Enriched bioactive kidney cell populations, their characteristics and uses
Patent Information
- Application Number
- JP2023528161
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-14
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-19
AI Technical Summary
Current treatments for chronic kidney disease (CKD) are ineffective in preventing or slowing disease progression, and there is a need for therapeutic approaches that can enhance renal function and improve quality of life in patients with CKD.
Identification of enriched heterogeneous renal cell populations expressing nephrogenic markers such as SIX2, OSR1, LHX1, RET, and FGF8, which are administered to restore renal function, reduce fibrosis, and induce nephrogenesis.
The identified renal cell populations demonstrate regenerative potential, restoring renal function, reducing inflammation and fibrosis, and promoting nephrogenesis, thereby improving kidney function and potentially reducing the need for dialysis or transplantation.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Background technology]
[0001] Chronic kidney disease (CKD) is characterized by progressive nephropathy that worsens without therapeutic intervention, ultimately leading to end-stage renal disease (ESRD). Prevalence data from the United States to Europe indicate that approximately 10% of the general population suffers from stage 1 to stage 3 CKD (European Society of Nephrology 2009 (ERA, 2009), United States Renal Disease Data System 2011 (USRDS, 2011), non-patent literature 1). While the incidence and prevalence of CKD and ESRD are increasing worldwide, treatment outcomes remain poor (non-patent literature 2). In the United States alone, the prevalence of chronic kidney disease increased by more than 33% between 1996 and 2006 (non-patent literature 3). The increasing incidence of CKD poses a significant public health threat, and its impact is only predicted to grow.
[0002] The leading cause of ESRD is diabetes mellitus (Non-Patent Document 4), and the incidence of CKD continues to increase, primarily due to the increasing prevalence of type 2 diabetes (Non-Patent Document 4). CKD is often associated with adverse outcomes due to underlying comorbidities and / or risk factors, including hypertension and renovascular disease (Non-Patent Document 5, Non-Patent Document 6). Due to severe comorbidities, patients with CKD are 5 to 11 times more likely to die prematurely than survive and progress to ESRD (Non-Patent Document 7, Non-Patent Document 8). ESRD patients require renal replacement therapy (dialysis or transplantation) to survive. Currently, more than 500,000 people in the United States require dialysis or kidney transplantation, accounting for more than $22 billion annually in Medicare costs (6% of the total Medicare budget) (Non-Patent Document 9). Kidney transplantation is the definitive standard of care for CKD and provides better long-term survival (and cost-effectiveness) than dialysis, yet organs remain chronically in short supply. Despite an increase in both cadaveric and living kidney donors, the transplant rate per 100 dialysis patient-years in the United States has actually decreased. Preventing or delaying adverse outcomes of CKD by intervening early in the disease is a major strategy in CKD management. Unfortunately, early treatment approaches to prevent disease progression have not been successful.
[0003] New therapeutic paradigms, including tissue engineering and cell-based applications, can result in substantial and sustained enhancement of kidney function, slowing disease progression and improving quality of life in this patient population. These next-generation regenerative medicine technologies offer isolated kidney cells as a treatment option for CKD (US Pat. No. 6,323,493 to Presnell et al. and US Pat. No. 6,323,494 to Ilagan et al.). Injection of these bioactive kidney cells into the kidneys of animal models of CKD resulted in significant improvements in animal survival and kidney function.
[0004] There is a need in the art to identify cells with therapeutic potential for the treatment of kidney disease based on their regenerative or nephrogenic capacity and to ensure that renal cell-based therapeutics meet expected levels of efficacy. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] International Publication No. 2010 / 056328 [Patent Document 2] International Application No. PCT / US2011 / 036347 [Non-patent literature]
[0006] [Non-Patent Document 1] Jha et al., "Chronic kidney disease: global dimensions and perspectives." Lancet. 2013; 382:260-72 [Non-patent document 2] Shaw et al., "Global estimates of the prevalence of diabetes for 2010 and 2030." Diabetes Res Clin Pract. 2010; 87:4-14 [Non-patent document 3] US Renal Data System. Costs of CKD and ESRD. Minneapolis, MN, 2007 [Non-patent document 4] Postma and de Zeeuw, 2009 [Non-patent document 5] Khan et al., 2002 [Non-patent document 6] Stenvinkel P., "Chronic kidney disease - a public health priority and harbinger of premature cardiovascular disease." J Intern med. 2010; 268:456-67 [Non-Patent Document 7] Collins et al., 2003 [Non-patent document 8] Smith et al., 2004 [Non-Patent Document 9] Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. Rockville, MD: HHS / HRSA / HSB / DOT, 2008 Summary of the Invention
[0007] The present disclosure describes a method for identifying an enriched heterogeneous renal cell population as having therapeutic potential. In the method, it is determined whether cells of the enriched heterogeneous renal cell population express at least one nephrogenic marker. If the cells of the enriched heterogeneous renal cell population express at least one nephrogenic marker, the enriched heterogeneous renal cell population is identified as having therapeutic potential. The at least one nephrogenic marker includes one or more of SIX2, OSR1, LHX1, RET, and FGF8.
[0008] The present disclosure also describes a further method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, in which the expression level of one or more of the following genes by cells of the enriched heterogeneous renal cell population is determined: RHAMM, C2, C3, C4, fibrinogen, coagulation factor XIII, TEK, KDR, Notch1, Notch3, Timp3, Vwf, Adam15, Gas6, Igfbp1, and Tm4sf4. The enriched heterogeneous renal cell population is identified as having therapeutic potential if the expression level of the one or more genes by cells of the enriched heterogeneous renal cell population is increased compared to the expression level of the one or more genes by cells of a control renal cell population.
[0009] The present disclosure describes yet another method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, in which the method determines whether cells of the enriched heterogeneous renal cell population express SIX2, OSR1, RET, and podocin. If the cells of the enriched heterogeneous renal cell population are determined to express SIX2, OSR1, RET, and podocin, the enriched heterogeneous renal cell population is identified as having therapeutic potential.
[0010] The present disclosure describes yet another method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, in which the method determines whether cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1. If the cells of the enriched heterogeneous renal cell population are determined to express nephrin, podocin, and LHX1, the enriched heterogeneous renal cell population is identified as having therapeutic potential. [Brief explanation of the drawings]
[0011] [Figure 1A] 1 is a table listing cell markers detected as expressed by cells of selected renal cell populations, e.g., enriched heterogeneous renal cell populations, the cellular origins for those markers, and structures in which cells expressing those markers may be involved in the development of the kidney. [Figure 1B]1B is a graph showing the percentage of cells in a selected renal cell population, e.g., an enriched heterogeneous renal cell population, as determined by fluorescence-activated cell sorting (FACS) to express the markers described in FIG. 1A. The mean percentage and 95% CI are presented. [Figure 2] This is a scatter plot of enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in the differentially expressed genes (DEG) set. The vertical axis represents the pathway name, and the horizontal axis represents the richness factor. The size and color of each point represent the number of differentially expressed genes in the pathway and the range of different Q values, respectively. The dark points for TGF-β signaling pathway, Salmonella infection, rheumatoid arthritis, pyrimidine metabolism, proteoglycans in cancer, pathways in cancer, other types of O-glycan biosynthesis, Legionellosis, Hippo signaling pathway, HTLV-1 infection, FoxO signaling pathway, drug metabolism - other enzymes, and cell cycle are all in the high Q value range, close to 1.00. The points for the AGE-RAGE signaling pathway in diabetic complications and amebiasis are all in the low Q value range, close to 0.00. The points for protein digestion and absorption, small cell lung cancer, ECM-receptor interactions, axon guidance, and arginine and proline metabolism are in the medium to low Q value range. [Figure 3] This is a graph of the annotation of the DEG set for KEGG pathways. [Figure 4] Violin box plot of the mean methylation level distribution of differentially methylated regions (DMRs). Hyper-DMR refers to DMRs that are hypermethylated in the sample, and hypo-DMR refers to DMRs that are hypomethylated in the sample. [Figure 5]Scatter plots from FACS analysis of cells for expression of (A) SIX2, (B) OSR1, (C) LHX1, (D) RET, (E) nephrin, (F) podocin, (G) FGF8, and (H) RACK-1. In the upper scatter plots for each of (A)-(H), an isotype control antibody was used to gate on negative cells. In the lower scatter plots for each of (A)-(H), antigen-specific antibodies were used to detect positive cells and gate them away from negative cells. The positive cell population is either to the right of the vertical axis or above the horizontal axis. DETAILED DESCRIPTION OF THE INVENTION
[0012] The kidney is a complex organ composed of many different cell types, including podocytes, mesangial cells, endothelial cells, fibroblasts, epithelial cells, and numerous stem and progenitor cell populations, organized throughout the renal parenchyma into discrete, specialized functional units, or nephrons, that serve to selectively filter electrolytes from the vasculature. This complexity of the kidney makes it extremely challenging to engineer solid kidney replacement structures.
[0013] The complex process of mammalian kidney development begins in a region of the mesoderm known as the intermediate mesoderm. The pronephros, or "first kidney," represents the first step in lineage commitment during kidney development from the intermediate mesoderm. The pronephros is a small, hollow sphere of epithelial tubular cells connected to the pronephric duct. The pronephric duct then elongates caudally, while the pronephros itself regresses. The intermediate mesoderm now forms the second kidney, the mesonephros, also known as the mesonephric duct. In females, this regresses, but in males, it eventually becomes the epididymis, the connective tissue between the testes and the bladder. The mesonephric kidney consists of approximately 30 tubules. The lateral tips of the mesonephric tubules fuse with the mesonephric duct, opening a passageway from the excretory area to the cloaca, which eventually becomes the bladder and rectum. Finally, the metanephros, or metanephric mesenchyme, arises from the ureteric bud, which buds from the nephric duct and branches extensively, with each new growing tip acquiring a cap-like aggregate of metanephric bud tissue, thereby giving rise to the lobulated metanephros.
[0014] Bidirectional signaling between the ureteric bud and metanephric mesenchyme ultimately mediates seminal events in nephrogenesis. At E10.5, the ureteric bud, an outgrowth of the renal duct, transmits signals to the surrounding metanephric mesenchyme, inducing the condensation of metanephric mesenchymal cells around the tip of the invading ureteric bud. These mesenchymal condensations then undergo a mesenchymal-epithelial transition to form primitive epithelial vesicles known as renal corpuscles. Continued branching of the ureteric bud leads to the development of components of the collecting duct system and renal pelvis. Meanwhile, the renal corpuscles undergo a systematic series of morphological changes, eventually fusing with the ureteric bud epithelium to form the S-shaped body, a continuous epithelial tubule. Endothelial cell invasion into the S-shaped body triggers the formation of the glomerular vasculature. Continued branching morphogenesis from the ureteric bud epithelium in response to signaling from the adjacent metanephric mesenchyme in turn leads to the induction of new aggregates of metanephric mesenchyme at the tip of the ureteric bud and the continuation of nephrogenic events. This iterative process of branching morphogenesis of the ureteric bud and induction of additional mesenchymal condensates continues along the radial axis of the developing kidney, inducing the youngest nephrons toward the periphery.
[0015] The molecular genetics underlying branching morphogenesis and concomitant nephrogenesis in the developing kidney are complex. Briefly, ureteric bud induction is triggered by upregulation of the secreted growth factor GDNF via its receptor RET. RET expression along the pronephric duct is highest at the site of ureteric bud formation. Knockout mutations of either GDNF or RET are embryonic lethal and associated with failure of ureteric budding and consequent cessation of kidney and ureter formation. Upregulation of GDNF expression is due to the action of transcription factors including PAX2, SIX1, SIX2, and SIX4.
[0016] The mesenchymal-epithelial transition during the transformation of metanephric mesenchymal condensates into renal corpuscles is primarily regulated by WNT family proteins, including WNT9b and WNT4. As a result, WNT4 knockout mice die within 24 hours of birth, and their kidneys are small, abnormal, and composed of undifferentiated metanephric mesenchyme. Other growth factors that regulate aspects of ureteric bud branching and nephrogenesis include TGF-β, FGF2, FGF7, LIF, and LIM1. Furthermore, multiple interacting signaling pathways are involved in regulating both aspects of ureteric bud branching and nephrogenesis. These include the classical WNT / β-catenin pathway, the sonic hedgehog pathway, and BMP and FGF members of the TGF-β superfamily signaling pathway.
[0017] Regionalization of intermediate mesoderm along the anterior / posterior axis is characterized by the expression of certain key transcription factors, including PAX2, PAX8, OSR1, and WT1. OSR1 initially determines intermediate mesoderm from paraxial and lateral plate fates but is nonetheless important for the determination and survival of cap mesenchyme. OSR1 expression is restricted to the cap mesenchyme, and OSR1-null mice fail to show expression of key cap mesenchyme genes (PAX2, SIX2, GDNF, EYA1, and SALL1). In contrast, OSR1 is not required for the formation of the FOXD1+ interstitial compartment, despite being expressed in metanephric mesenchyme prior to the separation of these lineages.
[0018] The WNT9b gene is expressed in the epithelial Wolffian duct before the induction of metanephric development. WNT9b expression continues in the ureteric bud, where its expression is more prominent in the stalk region than in the tip. In mice, WNT9b expression is maintained in the collecting duct until adulthood. WNT9b-mediated induction in the cap mesenchyme initiates the expression of genes encoding WNT4, fibroblast growth factor 8 (FGF8), paired box 8 (PAX8), and LIM homeobox protein 1 (LHX1). These genes fail to be expressed in the cap mesenchyme of WNT9b-deficient embryonic kidneys, resulting in the failure of nephron formation and the subsequent death of WNT9b knockout mice shortly after birth.
[0019] The observed expression of multiple markers typically associated with the earliest signaling events during embryonic nephrogenesis suggests that enriched heterogeneous renal cell populations, expanded after isolation from the kidney, may have dedifferentiated and acquired more renal progenitor-like characteristics. Thus, the introduction of these enriched heterogeneous renal cell populations with renal progenitor-like characteristics into diseased renal parenchyma may trigger the initiation of key signaling cascades that normally mediate nephrogenesis but that, in the context of adult parenchyma, are interpreted as regeneration.
[0020] Described herein are methods for identifying enriched heterogeneous renal cell populations as having therapeutic potential, heterogeneous renal cell populations identified as having therapeutic potential, and methods and uses of heterogeneous renal cell populations with therapeutic potential.
[0021] In methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, the therapeutic potential of the enriched heterogeneous renal cell population can be in the treatment of a kidney disease, a tubular transport defect, or a glomerular filtration defect.
[0022] When an enriched heterogeneous renal cell population is identified as having the potential to treat kidney disease, the kidney disease may be associated with any stage or degree of acute or chronic renal failure, which results in the kidney losing its ability to filter blood and remove excess water, electrolytes, and waste products from the blood. Kidney disease may include endocrine dysfunction, such as anemia, e.g., erythropoietin deficiency, and mineral imbalance, e.g., vitamin D deficiency. Kidney disease may originate in the kidney or may be secondary to another condition, e.g., heart failure, hypertension, diabetes, autoimmune disease, or liver disease. Alternatively, kidney disease may develop after acute injury to the kidney or may be the result of abnormalities in the kidney and / or urinary tract.
[0023] If the enriched heterogeneous renal cell population is identified as having therapeutic potential, the enriched heterogeneous renal cell population may restore renal function, stabilize renal function, improve renal function, reduce renal fibrosis, reduce renal inflammation, induce tubule formation in the kidney, induce nephrogenesis in the kidney, induce glomerular formation in the kidney, or have a regenerative effect in the kidney of a patient in need of such treatment. If the enriched heterogeneous renal cell population is identified as having therapeutic potential, the enriched heterogeneous renal cell population may restore mineral balance or alleviate anemia in a patient in need of such treatment. If the enriched heterogeneous renal cell population is identified as having therapeutic potential, the enriched heterogeneous renal cell population may prolong or prevent the need for dialysis, or prolong or prevent the need for a kidney transplant in a patient in need of treatment for kidney disease.
[0024] In a method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, it can be determined whether cells of the enriched heterogeneous renal cell population express at least one nephrogenic marker. The at least one nephrogenic marker whose expression is determined in the method can be any one of SIX homeobox 2 (SIX2), odd-skipped-related 1 (OSR1), LIM homeobox 1 (LHX1), rearranged during transfection (RET), or fibroblast growth factor 8 (FGF8). The at least one nephrogenic marker whose expression is determined in the method can be, or can include, any one, any two, any three, any four, or all of SIX2, OSR1, LHX1, RET, and FGF8.
[0025] In these methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, determining the expression of at least one nephrogenic marker can be or can include determining the expression of any two of the following nephrogenic markers: SIX2, OSR1, LHX1, RET, or FGF8. When determining the expression of any two of these nephrogenic markers, the two nephrogenic markers can be or can include SIX2 and OSR1, or SIX2 and LHX1, or SIX2 and RET, or SIX2 and FGF8, or OSR1 and LHX1, or OSR1 and RET, or OSR1 and FGF8, or LHX1 and RET, or LHX1 and FGF8, or RET and FGF8.
[0026] In methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, determining the expression of at least one nephrogenic marker can be or can include determining the expression of any three of the following nephrogenic markers: SIX2, OSR1, LHX1, RET, or FGF8. When determining the expression of any three of these nephrogenic markers, the three nephrogenic markers can be or can include SIX2, OSR1, and LHX1, or SIX2, OSR1, and RET, or SIX2, OSR1, and FGF8, or SIX2, LHX1, and RET, or SIX2, LHX1, and FGF8, or SIX2, RET, and FGF8, or OSR1, LHX1, and RET, or OSR1, LHX1, and FGF8, or OSR1, RET, and FGF8, or LHX1, RET, and FGF8.
[0027] In methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, determining the expression of at least one nephrogenic marker can be or can include determining the expression of any four of the following nephrogenic markers: SIX2, OSR1, LHX1, RET, or FGF8. When determining the expression of any four of these nephrogenic markers, the four nephrogenic markers can be or can include any of SIX2, OSR1, LHX1, and RET, or SIX2, OSR1, LHX1, and FGF8, or SIX2, LHX1, RET, and FGF8, or SIX2, OSR1, RET, and FGF8, or OSR1, LHX1, RET, and FGF8.
[0028] In methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, determining the expression of at least one nephrogenic marker may be or may include determining the expression of each of the following nephrogenic markers: SIX2, OSR1, LHX1, RET, and FGF8.
[0029] In methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, determining that the cells of the heterogeneous enriched renal cell population express at least one (e.g., any one, or any two, or any three, or any four, or all five) nephrogenic markers can identify the enriched heterogeneous renal cell population as having therapeutic potential.
[0030] In methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, determining the expression of at least one nephrogenic marker can further include determining the percentage of cells in the enriched heterogeneous renal cell population that express the at least one nephrogenic marker. When the percentage of cells in the enriched heterogeneous renal cell population that express the at least one nephrogenic marker is determined, the percentage of cells that express any one, any two, any three, any four, or all five of the following nephrogenic markers can be determined: SIX2, OSR1, LHX1, RET, and FGF8. When the percentage of cells in the enriched heterogeneous renal cell population that express at least one nephrogenic marker is determined, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if approximately a certain or specific percentage of cells in the enriched heterogeneous renal cell population express any one, any two, any three, any four, or all five of the nephrogenic markers SIX2, OSR1, LHX1, RET, and FGF8.
[0031] The percentage of cells in the enriched heterogeneous renal cell population that express SIX2 is determined in the above-described manner, and the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that at least about 0.02% of the cells in the enriched heterogeneous renal cell population express SIX2. Alternatively, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that the percentage of cells in the enriched heterogeneous renal cell population that express SIX2 is at least about 0.04%, or at least about 0.1%, or at least about 0.5%, or at least about 1.0%, or at least about 1.5%, or at least about 2.0%, or at least about 2.5%, or at least about 3.0%, or at least about 3.5%, or at least about 4.0%, or at least about 4.5%, or at least about 5.0%, or at least about 5.5%. An enriched heterogeneous renal cell population can be identified as having therapeutic potential when the percentage of cells in the enriched heterogeneous renal cell population that express SIX2 is determined to be greater than 0% up to at most about 15.0%, greater than 0% up to at most about 10.0%, or greater than 0% up to at most about 9.5%, or greater than 0% up to at most about 9.0%, or greater than 0% up to at most about 8.5%, or greater than 0% up to at most about 8.0%, or greater than 0% up to at most about 7.5%, or greater than 0% up to at most about 7.0%, or greater than 0% up to at most about 6.5%, or greater than 0% up to at most about 6.0%.Furthermore, the percentage of cells in the enriched heterogeneous kidney cell population that express SIX2 is between about 0.02% and about 15.0%, or between about 0.02% and about 10.0%, or between about 0.02% and about 9.0%, or between about 0.02% and about 8.0%, or between about 0.02% and about 7.0%, or between about 0.02% and about 6.0%, or between about 0.04% and about 15.0%, or between about 0.04% and about 10.0%, or between about 0.04% and about 9.0%, or between about An enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined to be between 0.04% and about 8.0%, or between about 0.04% and about 7.0%, or between about 0.04% and about 6.0%, or between about 1.0% and about 15.0%, or between about 1.0% and about 10.0%, or between about 1.0% and about 9.0%, or between about 1.0% and about 8.0%, or between about 1.0% and about 7.0%, or between about 1.0% and about 6.0%.
[0032] The percentage of cells in the enriched heterogeneous renal cell population that express OSR1 is determined in the above-described manner, and the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that at least about 30% of the cells in the enriched heterogeneous renal cell population express OSR1. Alternatively, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that the percentage of cells in the enriched heterogeneous renal cell population that express OSR1 is at least about 35%, or at least about 36%, or at least about 37%, or at least about 38%, or at least about 39%, or at least about 40%, or at least about 41%, or at least about 42%, or at least about 43%, or at least about 44%, or at least about 45%, or at least about 50%. An enriched heterogeneous renal cell population can be identified as having regenerative potential when the percentage of cells in the enriched heterogeneous renal cell population that express OSR1 is determined to be greater than 0% and up to about 90%, or greater than 0% and up to about 88%, or greater than 0% and up to about 86%, or greater than 0% and up to about 84%, or greater than 0% and up to about 82%, or greater than 0% and up to about 80%, or greater than 0% and up to about 75%, or greater than 0% and up to about 70%.Furthermore, the percentage of cells in the enriched heterogeneous kidney cell population that express OSR1 is between about 30% and about 90%, or between about 30% and about 88%, or between about 30% and about 86%, or between about 30% and about 84%, or between about 30% and about 82%, or between about 30% and about 80%, or between 34% and about 90%, or between about 34% and about 88%, or between about 34% and about 86%, or between about 34% and about 84%, or between about 34% and about 82%, or between about 34% and about 80%, or between about 36% and about 90%, or between about 36% and about 88%, or between about 36% and about 86%, or between about 36% and about 84%, or between about 36% and about 86%. An enriched heterogeneous kidney cell population can be identified as having regenerative potential if its cell density is determined to be between about 82%, or between about 36% and about 80%, or between about 40% and about 90%, or between about 40% and about 85%, or between about 45% and about 90%, or between about 45% and about 85%, or between about 50% and about 90%, or between about 50% and about 85%, or between about 55% and about 90%, or between about 55% and about 85%, or between about 60% and about 90%, or between about 60% and about 85%, or between about 65% and about 90%, or between about 65% and about 85%, or between about 70% and about 90%, or between about 70% and about 85%.
[0033] The percentage of cells in the enriched heterogeneous renal cell population that express LHX1 is determined in the above-described manner, and if it is determined that at least about 5% of the cells in the enriched heterogeneous renal cell population express LHX1, the heterogeneous enriched renal cell population can be identified as having regenerative potential. Alternatively, if it is determined that the percentage of cells in the enriched heterogeneous renal cell population that express LHX1 is at least about 6%, or at least about 7%, or at least about 8%, or at least about 9%, or at least about 10%, the heterogeneous renal cell population can be identified as having therapeutic potential. A heterogeneous renal cell population can be identified as having therapeutic potential when the percentage of cells in the enriched heterogeneous renal cell population that express LHX1 is determined to be greater than 0% and up to 75%, or greater than 0% and up to 70%, or greater than 0% and up to about 65%, or greater than 0% and up to about 64%, or greater than 0% and up to about 63%, or greater than 0% and up to about 62%, or greater than 0% and up to about 61%, or greater than 0% and up to about 60%, or greater than 0% and up to about 59%, or greater than 0% and up to about 58%, or greater than 0% and up to about 57%, or greater than 0% and up to about 56%, or greater than 0% and up to about 55%.Furthermore, the percentage of cells in the enriched heterogeneous kidney cell population that express LHX1 is between about 6% and about 60%, or between about 6% and about 59%, or between about 6% and about 58%, or between about 6% and about 57%, or between about 6% and about 56%, or between about 6% and about 55%, or between about 6% and about 54%, or between about 8% and about 60%, or between about 8% and about 59%, or between about 8% and about 58%, or between about 8% and about 57%, or between about 8% and about 56%, or between about 8% and about 55%, or between about 8% and about 54%, or between about 10% and about 60%, or between about 10% and about 59%, or between about 10% and about 58%, or between about 10% and about 57%, or between about 10% and about 58%. An enriched heterogeneous renal cell population can be identified as having regenerative potential when the cell density is determined to be between about 10% and about 56%, or between about 10% and about 55%, or between about 10% and about 54%, or between about 16% and 80%, or between about 16% and 70%, or between about 16% and about 60%, or between about 16% and about 58%, or between about 16% and about 56%, or between about 16% and about 54%, or between about 16% and about 52%, or between about 16% and about 50%, or between 22% and about 60%, or between about 22% and about 58%, or between about 22% and about 56%, or between about 22% and about 54%, or between about 22% and about 52%, or between about 22% and about 50%.
[0034] The percentage of cells in the enriched heterogeneous renal cell population that express RET is determined in the above-described manner, and the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that at least about 45% of the cells in the enriched heterogeneous renal cell population express RET. Alternatively, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that the percentage of cells in the enriched heterogeneous renal cell population that express RET is at least about 22%, at least about 24%, at least about 26%, at least about 28%, at least about 30%, at least about 32%, at least about 34%, at least about 36%, at least about 38%, at least about 40%, at least about 42%, at least about 44%, at least about 46%, or at least about 47%, or at least about 48%, or at least about 49%, or at least about 50%, or at least about 51%, or at least about 52%, or at least about 53%, or at least about 54%. An enriched heterogeneous renal cell population can be identified as having therapeutic potential when the percentage of cells in the enriched heterogeneous renal cell population that express RET is determined to be greater than 0% up to at most about 95%, or greater than 0% up to at most about 94%, or greater than 0% up to at most about 93%, or greater than 0% up to at most about 92%, or greater than 0% up to at most about 91%, or greater than 0% up to at most about 90%, or greater than 0% up to at most about 89%, or greater than 0% up to at most about 88%, or greater than 0% up to at most about 87%, or greater than 0% up to at most about 86%, or greater than 0% up to at most about 85%.Furthermore, the percentage of cells in the enriched heterogeneous kidney cell population that express RET is between about 45% and about 95%, or between about 45% and about 94%, or between about 45% and about 93%, or between about 45% and about 92%, or between about 45% and about 91%, or between about 45% and about 90%, or between about 45% and about 89%, or between about 45% and about 88%, or between about 47% and about 95%, or between about 47% and about 94%, or between about 47% and about 93%, or between about 47% and about 92%, or between about 47% and about 91%, or between about 47% and about 90%, or between about 47% and about 89%, or between about 47% and about 88%, or between about 49% and about 95%, or between about 49% and about 95%. An enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined to be between about 94%, or between about 49% and about 93%, or between about 49% and about 92%, or between about 49% and about 91%, or between about 49% and about 90%, or between about 49% and about 89%, or between about 49% and about 88%, or between about 20% and about 60%, or between about 20% and about 55%, or between about 20% and about 50%, or between about 20% and about 45%, or between about 20% and about 40%, or between about 25% and about 60%, or between about 25% and about 55%, or between about 25% and about 50%, or between about 25% and about 45%, or between about 25% and about 40%.
[0035] The percentage of cells in the enriched heterogeneous renal cell population that express FGF8 is determined in the above-described manner, and the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that at least about 0.2% of the cells in the enriched heterogeneous renal cell population express FGF8. Alternatively, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that the percentage of cells in the enriched heterogeneous renal cell population that express FGF8 is at least about 0.25%, or at least about 0.3%, or at least about 0.35%, or at least about 0.4%, or at least about 0.45%, or at least about 0.48%, or at least about 0.5%, or at least about 0.55%, or at least about 0.6%, or at least about 0.8%, or at least about 1.0%, or at least about 1.5%, or at least about 2.0%, or about 2.5%. An enriched heterogeneous renal cell population can be identified as having therapeutic potential when the percentage of cells in the enriched heterogeneous renal cell population that express FGF8 is determined to be greater than 0% up to at most about 65%, or greater than 0% up to at most about 64%, or greater than 0% up to at most about 63%, or greater than 0% up to at most about 62%, or greater than 0% up to at most about 61%, or greater than 0% up to at most about 60%, or greater than 0% up to at most about 59% or at most about 58%, or greater than 0% up to at most about 57%, or greater than 0% up to at most about 56%, or greater than 0% up to at most about 55%.Furthermore, the percentage of cells in the enriched heterogeneous kidney cell population that express FGF8 is between about 0.3% and about 64%, or between about 0.3% and about 63%, or between about 0.3% and about 62%, or between about 0.3% and about 61%, or between about 0.3% and about 60%, or between about 0.3% and about 59%, or between about 0.3% and about 58%, or between about 0.3% and about 57%, or about 0. Between 4% and about 64%, or between about 0.4% and about 63%, or between about 0.4% and about 62%, or between about 0.4% and about 61%, or between about 0.4% and about 60%, or between about 0.4% and about 59%, or between about 0.4% and about 58%, or between about 0.4% and about 57%, or between about 0.5% and about 64%, or between about 0.5% and about 63%, or between about 0.5% and about 62% , or between about 0.5% and about 61%, or between about 0.5% and about 60%, or between about 0.5% and about 59%, or between about 0.5% and about 58%, or between about 0.5% and about 57%, or between about 1% and about 64%, or between about 1% and about 54%, or between about 1% and about 44%, or between about 1% and about 34%, or between 1% and about 24%, or between about 2% and about 64%, or about 2% An enriched heterogeneous renal cell population can be identified as having therapeutic potential when the enriched heterogeneous renal cell population is determined to be between about 2% and about 54%, or between about 2% and about 44%, or between about 2% and about 34%, or between 2% and about 24%, or between about 3% and about 64%, or between about 3% and about 54%, or between about 3% and about 44%, or between about 3% and about 34%, or between 3% and about 24%.
[0036] A method of identifying an enriched heterogeneous renal cell population as having therapeutic potential can include determining the percentage of cells in the heterogeneous renal cell population that express a combination of any two, any three, any four, or all five of the nephrogenic markers SIX2, OSR1, LHX1, RET, and FGF8. For example, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if a combination of any two, any three, any four, or all five of the following is determined: greater than 0% and up to about 6% of the cells in the heterogeneous renal cell population express SIX2, at least about 36% of the cells in the heterogeneous renal cell population express OSR1, at least about 8% of the cells in the enriched heterogeneous renal cell population express LHX1, at least about 49% of the cells in the enriched heterogeneous renal cell population express RET, and / or greater than 0% and up to about 59% of the cells in the enriched heterogeneous renal cell population express FGF8. In another example, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: at least about 0.04% of the cells in the enriched heterogeneous renal cell population express SIX2; greater than 0% and up to about 85% of the cells in the enriched heterogeneous renal cell population express OSR1; greater than 0% and up to about 58% of the cells in the enriched heterogeneous renal cell population express LHX1; greater than 0% and up to about 90% of the cells in the enriched heterogeneous renal cell population express RET; and / or at least about 0.48% of the cells in the enriched heterogeneous renal cell population express FGF8.An enriched heterogeneous renal cell population can be further identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: between about 0.04% and about 6.0% of the cells in the enriched heterogeneous renal cell population express SIX2, between about 36% and about 85% of the cells in the enriched heterogeneous renal cell population express OSR1, between about 8% and about 58% of the cells in the enriched heterogeneous renal cell population express LHX1, between about 49% and about 90% of the cells in the enriched heterogeneous renal cell population express RET, and between about 0.48% and / or about 59% of the cells express FGF8. Combinations of any two, any three, any four, or all five nephrogenic markers whose expression can be determined in these percentages include SIX2 and OSR1, or SIX2 and LHX1, or SIX2 and RET, or SIX2 and FGF8, or OSR1 and LHX1, or OSR1 and RET, or OSR1 and FGF8, or LHX1 and RET, or LHX1 and FGF8, or RET and FGF8, or SIX2, OSR1, and LHX1, or SIX2, OSR1, and RET, or SIX2, OSR1, and FGF8, or SIX2, LHX1, and RET, Or it may be any combination of SIX2, LHX1, and FGF8, or SIX2, RET, and FGF8, or OSR1, LHX1, and RET, or OSR1, LHX1, and FGF8, or OSR1, RET, and FGF8, or LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, and RET, SIX2, OSR1, LHX1, and FGF8, SIX2, LHX1, RET, and FGF8, SIX2, OSR1, RET, and FGF8, OSR1, LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, RET, and FGF8.
[0037] In methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, the enriched heterogeneous renal cell population can alternatively be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: greater than 0% and up to about 10% of the cells in the heterogeneous renal cell population express SIX2; at least about 30% of the cells in the enriched heterogeneous renal cell population express OSR1; at least about 5% of the cells in the enriched heterogeneous renal cell population express LHX1; at least about 40% of the cells in the enriched heterogeneous renal cell population express RET; and / or greater than 0% and up to about 60% of the cells in the enriched heterogeneous renal cell population express FGF8. In another example, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: at least about 0.02% of the cells in the enriched heterogeneous renal cell population express SIX2; greater than 0% and up to about 90% of the cells in the enriched heterogeneous renal cell population express OSR1; greater than 0% and up to about 65% of the cells in the enriched heterogeneous renal cell population express LHX1; greater than 0% and up to about 95% of the cells in the enriched heterogeneous renal cell population express RET; and / or at least about 0.4% of the cells in the enriched heterogeneous renal cell population express FGF8. Furthermore, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: between about 0.02% and about 10.0% of the cells in the enriched heterogeneous renal cell population express SIX2; between about 30% and about 90% of the cells in the enriched heterogeneous renal cell population express OSR1; between about 5% and about 65% of the cells in the enriched heterogeneous renal cell population express LHX1; between about 40% and about 95% of the cells in the enriched heterogeneous renal cell population express RET; and / or between about 0.4% and about 60% of the cells express FGF8.Combinations of any two, any three, any four, or all five nephrogenic markers whose expression can be determined in these percentages include SIX2 and OSR1, or SIX2 and LHX1, or SIX2 and RET, or SIX2 and FGF8, or OSR1 and LHX1, or OSR1 and RET, or OSR1 and FGF8, or LHX1 and RET, or LHX1 and FGF8, or RET and FGF8, or SIX2, OSR1, and LHX1, or SIX2, OSR1, and RET, or SIX2, OSR1, and FGF8, or SIX2, LHX1, and RET, Or it may be any combination of SIX2, LHX1, and FGF8, or SIX2, RET, and FGF8, or OSR1, LHX1, and RET, or OSR1, LHX1, and FGF8, or OSR1, RET, and FGF8, or LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, and RET, SIX2, OSR1, LHX1, and FGF8, SIX2, LHX1, RET, and FGF8, SIX2, OSR1, RET, and FGF8, OSR1, LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, RET, and FGF8.
[0038] In a method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: greater than 0% and up to about 3% of the cells in the heterogeneous renal cell population express SIX2; at least about 60% of the cells in the enriched heterogeneous renal cell population express OSR1; at least about 25% of the cells in the enriched heterogeneous renal cell population express LHX1; at least about 65% of the cells in the enriched heterogeneous renal cell population express RET; and / or greater than 0% and up to about 35% of the cells in the enriched heterogeneous renal cell population express FGF8. In another example, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: at least about 0.5% of the cells in the enriched heterogeneous renal cell population express SIX2; greater than 0% and up to about 80% of the cells in the enriched heterogeneous renal cell population express OSR1; greater than 0% and up to about 55% of the cells in the enriched heterogeneous renal cell population express LHX1; greater than 0% and up to about 90% of the cells in the enriched heterogeneous renal cell population express RET; and / or at least about 5% of the cells in the enriched heterogeneous renal cell population express FGF8. Furthermore, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: between about 0.5% and about 3.0% of the cells in the enriched heterogeneous renal cell population express SIX2; between about 60% and about 80% of the cells in the enriched heterogeneous renal cell population express OSR1; between about 25% and about 55% of the cells in the enriched heterogeneous renal cell population express LHX1; between about 65% and about 90% of the cells in the enriched heterogeneous renal cell population express RET; and / or between about 5% and about 35% of the cells express FGF8.Combinations of any two, any three, any four, or all five nephrogenic markers whose expression can be determined in these percentages include SIX2 and OSR1, or SIX2 and LHX1, or SIX2 and RET, or SIX2 and FGF8, or OSR1 and LHX1, or OSR1 and RET, or OSR1 and FGF8, or LHX1 and RET, or LHX1 and FGF8, or RET and FGF8, or SIX2, OSR1, and LHX1, or SIX2, OSR1, and RET, or SIX2, OSR1, and FGF8, or SIX2, LHX1, and RET, Or it may be any combination of SIX2, LHX1, and FGF8, or SIX2, RET, and FGF8, or OSR1, LHX1, and RET, or OSR1, LHX1, and FGF8, or OSR1, RET, and FGF8, or LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, and RET, SIX2, OSR1, LHX1, and FGF8, SIX2, LHX1, RET, and FGF8, SIX2, OSR1, RET, and FGF8, OSR1, LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, RET, and FGF8.
[0039] In a method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: greater than 0% and up to about 10% of the cells in the heterogeneous renal cell population express SIX2; at least about 35% of the cells in the enriched heterogeneous renal cell population express OSR1; at least about 8% of the cells in the enriched heterogeneous renal cell population express LHX1; at least about 20% of the cells in the enriched heterogeneous renal cell population express RET; and / or greater than 0% and up to about 60% of the cells in the enriched heterogeneous renal cell population express FGF8. In another example, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: at least about 0.2% of the cells in the enriched heterogeneous renal cell population express SIX2; greater than 0% and up to about 85% of the cells in the enriched heterogeneous renal cell population express OSR1; greater than 0% and up to about 65% of the cells in the enriched heterogeneous renal cell population express LHX1; greater than 0% and up to about 90% of the cells in the enriched heterogeneous renal cell population express RET; and / or at least about 0.5% of the cells in the enriched heterogeneous renal cell population express FGF8. Furthermore, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if any two, any three, any four, or all five of the following are determined: between about 0.2% and about 10.0% of the cells in the enriched heterogeneous renal cell population express SIX2; between about 35% and about 85% of the cells in the enriched heterogeneous renal cell population express OSR1; between about 8% and about 65% of the cells in the enriched heterogeneous renal cell population express LHX1; between about 20% and about 90% of the cells in the enriched heterogeneous renal cell population express RET; and / or between about 0.5% and about 60% of the cells express FGF8.Combinations of any two, any three, any four, or all five nephrogenic markers whose expression can be determined in these percentages include SIX2 and OSR1, or SIX2 and LHX1, or SIX2 and RET, or SIX2 and FGF8, or OSR1 and LHX1, or OSR1 and RET, or OSR1 and FGF8, or LHX1 and RET, or LHX1 and FGF8, or RET and FGF8, or SIX2, OSR1, and LHX1, or SIX2, OSR1, and RET, or SIX2, OSR1, and FGF8, or SIX2, LHX1, and RET, Or it may be any combination of SIX2, LHX1, and FGF8, or SIX2, RET, and FGF8, or OSR1, LHX1, and RET, or OSR1, LHX1, and FGF8, or OSR1, RET, and FGF8, or LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, and RET, SIX2, OSR1, LHX1, and FGF8, SIX2, LHX1, RET, and FGF8, SIX2, OSR1, RET, and FGF8, OSR1, LHX1, RET, and FGF8, or SIX2, OSR1, LHX1, RET, and FGF8.
[0040] When the percentage of cells expressing a particular marker is stated as being "about" a particular percentage of a particular number, e.g., about 5%, it is understood that the percentage of cells need not be exactly that particular number, e.g., exactly 5%. Rather, when the percentage of cells expressing a particular marker is stated as being "about" a particular number, e.g., about 5%, it is understood that the percentage of cells expressing the particular marker can be up to 10% of that particular number, e.g., between 4.5% and 5.5%.
[0041] In methods for identifying an enriched heterogeneous renal cell population as having therapeutic potential, it can be determined whether cells of the enriched heterogeneous renal cell population express one or more additional markers, i.e., markers other than the nephrogenic markers SIX2, OSR1, LHX1, RET, and FGF8. The one or more additional markers can be or include one or more of a podocyte marker, an epithelial marker, a developmental marker, or an miRNA. When the one or more additional markers include a podocyte marker, the one or more additional markers can include one or more of nephrin, EpiCAM, NPHS2 (encoding podocin), podocin, Wilms' tumor protein (WT1), or podocalyxin. When the one or more additional markers include an epithelial cell marker, the one or more additional markers can include one or more of E-cadherin, N-cadherin, cubulin / megalin, vitamin D-25 hydroxylase (CYP2R1), gamma-glutamyltransferase 1 (GGT1), liver-enriched transcription protein (LAP), cytokeratin (CK) 18, aquaporin (AQP) 2, kidney injury molecule (KIM1), erythropoietin (EPO), kinase insert domain receptor (KDR), epithelial cell adhesion molecule (ECAM), or AQP1. When the one or more additional markers include a developmental marker, the developmental marker can include one or more of neutrophil gelatinase-associated lipocalin (NGAL), sonic hedgehog (SHH), NOTCH, C-X-C motif chemokine receptor 4 (CXCR4), lunatic fringe (LFNG), or IL-11. The one or more additional markers may be or may include receptor for activated C kinase 1 (RACK-1). If the one or more additional markers include a miRNA, the miRNA may be one or more of miR22, miR181, or miR145.
[0042] When the one or more additional markers include a podocyte marker, the podocyte marker can be nephrin. In such a method, when it is further determined that cells of the enriched heterogeneous renal cell population express nephrin, the enriched heterogeneous renal cell population can be identified as having therapeutic potential. When the one or more additional markers is or includes nephrin, the percentage of cells of the enriched heterogeneous renal cell population that express nephrin can be determined. When the percentage of cells in the enriched heterogeneous renal cell population that express nephrin is determined, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the cells in the heterogeneous renal cell population express nephrin. When the percentage of cells of the enriched heterogeneous renal cell population that express nephrin is determined, it is generally between about 4% and about 95%, or between about 10% and about 95%, or between about 15% and about 95%, or between about 20% and about 95%, or between about 25% and about 95%, and between about 30% and about 95%, or between 35% and about 95%, or between about 40% and about 95%, or about 45% or An enriched heterogeneous renal cell population can be identified as having therapeutic potential if between about 50% and about 95%, or between about 55% and about 95%, or between about 60% and about 95%, or between about 65% and about 95%, or between 70% and about 95%, or between about 75% and about 95%, or between about 80% and about 95%, or between about 85% and about 95% express nephrin.
[0043] When the one or more additional markers are or include a podocyte marker, the podocyte marker can be podocin. In such methods, when it is further determined that the cells of the enriched heterogeneous renal cell population express podocin, the enriched heterogeneous renal cell population can be identified as having therapeutic potential. When the one or more additional markers are or include podocin, the percentage of cells of the enriched heterogeneous renal cell population that express podocin can be determined. When the percentage of cells of the enriched heterogeneous renal cell population that express podocin is determined, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, or at least about 98% of the cells of the heterogeneous renal cell population express podocin.
[0044] When the one or more additional markers include a podocyte marker, the podocyte marker may include both nephrin and podocin. In such a method, when it is further determined that cells of the enriched heterogeneous renal cell population express nephrin and podocin, the enriched heterogeneous renal cell population can be identified as having therapeutic potential. When the one or more additional markers include nephrin and podocin, the percentage of cells of the enriched heterogeneous renal cell population that express nephrin and podocin can be determined.When the percentage of cells of the enriched heterogeneous kidney cell population that express nephrin and podocin is determined, the enriched kidney cell population is considered to be enriched if at least 4% of the cells express nephrin and at least about 90% of the cells express podocin, or if at least 8% of the cells express nephrin and at least about 90% of the cells express podocin, or if at least 10% of the cells express nephrin and at least about 90% of the cells express podocin, or if at least 12% of the cells express nephrin and at least about 90% of the cells express podocin. or when at least 14% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 20% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 25% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 30% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 35% of the cells express nephrin, and at least about 90% of the cells express podocin, or when at least 40% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 45% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 50% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 55% of the cells express nephrin and at least about 90% of the cells express podocin, or when at least 50% of the cells express nephrin and at least about 90% of the cells express podocin. An enriched heterogeneous renal cell population can be identified as having therapeutic potential if at least 60% express nephrin and at least about 90% of the cells express podocin, or if at least 65% of the cells express nephrin and at least about 90% of the cells express podocin, or if at least 70% of the cells express nephrin and at least about 90% of the cells express podocin, or if at least 75% of the cells express nephrin and at least about 90% of the cells express podocin.
[0045] When the one or more additional markers are or include RACK-1, the cell population can be identified as having therapeutic potential if the cells of the enriched heterogeneous renal cell population express RACK-1. When the one or more additional markers are or include RACK-1, the percentage of cells of the enriched heterogeneous renal cell population that express RACK-1 can be determined. When the percentage of cells of the enriched heterogeneous renal cell population that express RACK-1 is determined, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, or at least about 98% of the cells of the heterogeneous renal cell population express RACK-1.
[0046] When the one or more additional markers include an epithelial cell marker, the epithelial cell marker can be CYP2R1. In such a method, when cells of the enriched heterogeneous renal cell population are further determined to express CYP2R1, the enriched heterogeneous renal cell population can be identified as having therapeutic potential. When the one or more additional markers is or includes CYP2R1, the percentage of cells of the enriched heterogeneous renal cell population that express CYP2R1 can be determined. When the percentage of cells in the enriched heterogeneous renal cell population that express CYP2R1 is determined, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if between about 75% and about 100%, or between about 80% and about 100%, or between about 85% and about 100%, or between about 86% and about 100%, or between about 87% and about 100%, or between about 88% and about 100%, or between about 75% and about 97%, or between about 80% and about 97%, or between about 85% and about 97%, or between about 86% and about 97%, or between about 87% and about 97%, or between about 88% and about 97% of the cells in the heterogeneous renal cell population express CYP2R1.
[0047] When the one or more additional markers include a developmental marker, the developmental marker can be CXCR4. In such methods, if it is further determined that cells of the enriched heterogeneous renal cell population express CXCR4, the enriched heterogeneous renal cell population can be identified as having therapeutic potential. When the one or more additional markers are or include CXCR4, the percentage of cells of the enriched heterogeneous renal cell population that express CXCR4 can be determined. When the percentage of cells of the enriched heterogeneous renal cell population that express CXCR4 is determined, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if more than about 15%, more than about 16%, more than about 17%, more than about 18%, more than about 19%, more than about 20%, more than about 21%, more than about 22%, more than about 23%, more than about 24%, or more than about 25% of the cells of the heterogeneous renal cell population express CXCR4.
[0048] The one or more additional markers may include one or more combinations of bone morphogenetic protein (BMP) 4, BMP7, glial cell line-derived neurotrophic factor (GDNF), homeobox protein HOX11, eyes absent homolog 1 (EYA1), SAL1, and SIX4 (SIX homeobox 4). The one or more additional markers may include one or more combinations of paired box 2 (PAX2), Cbp / P300 interacting transactivator with Glu / Asp rich carboxy-terminal domain 1 (CITED1), fibroblast growth factor receptor (FGFR) 1, FGF7, FGF10, homeobox protein HOX10, capsuling / edicardin / Tcf21 (POD1), and mucin 1 (MUC1). The one or more additional markers may include one or more combinations of Receptor for Hyaluronan-Mediated Motility (RHAMM), complement component C2, complement component C3, complement component C4, fibrinogen, coagulation factor XIII, TEK tyrosine kinase, KDR, Notch1, Notch3, Timp3, von Willebrand factor (VWF), Adam15, Growth arrest-specific 6 (Gas6), insulin-like growth factor binding protein (Igfbp)1, or Transmembrane 4 Superfamily member 4 (Tm4sf4). The one or more additional markers may include RHAMM.
[0049] One or more additional markers may be CDKN2A, interleukin 11 (IL11), transforming growth factor (TGF) beta 2, fibronectin (FN) 1, cysteine-rich secretory protein LCCL domain containing 2 (CRISPLD2), type 1 collagen alpha 1 chain (COL1A1), lysyl oxidase (LOX), runt-related transcription factor 2 (RUNX2), lunatic fringe (LFNG), brain-derived neurotrophic factor (BDNF), claudin (CLDN) 3, uridine phosphorylase (UPP) 1, Krüppel-like factor (KLF) 14, glycosyltransferase-like (GYLTL) 1B, alpha-mannosidase class 1C member 1, or alpha-mannosidase class 1C member 1. The proteins may include one or more combinations of: mannitol esterase 1 (MAN1C1), polypeptide N-acetylgalactosaminyltransferase 9 (GALNT9), aquaporin (AQP1), solute carrier family 47 member 1 (SLC47A1), WNK lysine-deficient protein kinase (WNK)2, calcium-sensing receptor (CASR), retinoic acid induced 2 (RAI2), plasma membrane vesicle-associated protein (PLVAP), shisa family member (SHISA)3, prostate androgen-regulated mucin-like protein 1 (PARM1), FGF11, forkhead box E1 (FOXE1), WNT family member (WNT)5A, WNT10A, TGFβ1, and insulin-like growth factor binding protein (IGFBP)3. The one or more additional markers may include any one or more of IL11, TGFβ2, CRISPLD2, LOX, LNFG, BDNF, WNT5A, or IGFBP3.
[0050] In some methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, it can be determined whether the cells of the enriched heterogeneous renal cell population express SIX2, OSR1, RET, and podocin. In such methods, if it is determined that the cells of the enriched heterogeneous renal cell population express SIX2, OSR1, RET, and podocin, the enriched heterogeneous renal cell population can be identified as having therapeutic potential. Determining that the cells of the enriched heterogeneous renal cell population express SIX2, OSR, RET, and podocin can include determining the percentage of cells of the enriched heterogeneous renal cell population that express SIX2, OSR, RET, and podocin.
[0051] When determining that the cells of the enriched heterogeneous renal cell population express SIX2, OSR, RET, and podocin includes determining the percentage of cells of the enriched heterogeneous renal cell population that express SIX2, OSR, RET, and podocin, (i) the percentage of cells of the population that express SIX2 is greater than 0% and up to at most 15.0%, or greater than 0% and up to at most about 10.0%, or greater than 0% and up to at most about 9.5%, or greater than 0% and up to at most about 9.0%, or greater than 0% and up to at most about 8.5%, or greater than 0% and up to at most about 8.0%, or 0% greater than but not greater than about 7.5%, or greater than 0% but not greater than about 7.0%, or greater than 0% but not greater than about 6.5%, or greater than 0% but not greater than about 6.0%, or between about 0.02% and about 15%, or between about 0.02% and about 10.0%, or between about 0.02% and about 9.0%, or between about 0.02% and about 8.0%, or between about 0.02% and about 7.0%, or between about 0.02% and about 6.0%, or between about 0.04% and about 15%, or between about 0.04% and about 10.0%, or between about 0.04% and about 9.0%, or between about 0.04% and about 8.0% or between about 0.04% and about 7.0%, or between about 0.04% and about 6.0%, or between about 1.0% and about 15.0%, or between about 1.0% and about 10.0%, or between about 1.0% and about 9.0%, or between about 1.0% and about 8.0%, or between about 1.0% and about 7.0%, or between about 1.0% and about 6.0%, and (ii) the percentage of cells in the population that express OSR is greater than 0% and at most about 90%, or greater than 0% and at most about 88%, or greater than 0% and at most about 86%, or greater than 0% and at most about 84%, or greater than 0% and at most up to about 82%, or from greater than 0% to at most about 80%, or from greater than 0% to at most about 75%, or from greater than 0% to at most about 70%, between about 30% and about 90%, or between about 30% and about 88%, or between about 30% and about 86%, or between about 30% and about 84%, or between about 30% and about 82%, or between about 30% and about 80%, or between 34% and about 90%, or between about 34% and about 88%, or between about 34% and about 86%, or between about 34% and about 84%, or between about 34% and about 82%, or between about 34% and about 80%, or between about 36% and about 90%;or between about 36% and about 88%, or between about 36% and about 86%, or between about 36% and about 84%, or between about 36% and about 82%, or between about 36% and about 80%, or between about 40% and about 90%, or between about 40% and about 85%, or between about 45% and about 90%, or between about 45% and about 85%, or between about 50% and about 90%, or between about 50% and about 85%, or between about 55% and about 90%, or between about 55% and about 85%, or between about 60% and about 90%, or between about 60% and about 85%, or between about 65% and about 90%, or between about 65% and about 85%. 5%, or between about 70% and about 90%, or between about 70% and about 85%, and (iii) the percentage of cells in the population that express RET is greater than 0% up to at most about 94%, or greater than 0% up to at most about 93%, or greater than 0% up to at most about 92%, or greater than 0% up to at most about 91%, or greater than 0% up to at most about 90%, or greater than 0% up to at most about 89%, or greater than 0% up to at most about 88%, or greater than 0% up to at most about 87%, or greater than 0% up to at most about 86%, or greater than 0% up to at most about 85%, or between about 45% and about 95%. , or between about 45% and about 94%, or between about 45% and about 93%, or between about 45% and about 92%, or between about 45% and about 91%, or between about 45% and about 90%, or between about 45% and about 89%, or between about 45% and about 88%, or between about 47% and about 95%, or between about 47% and about 94%, or between about 47% and about 93%, or between about 47% and about 92%, or between about 47% and about 91%, or between about 47% and about 90%, or between about 47% and about 89%, or between about 47% and about 88%, or between about 49% and about 95% 94%, or between about 49% and about 93%, or between about 49% and about 92%, or between about 49% and about 91%, or between about 49% and about 90%, or between about 49% and about 89%, or between about 49% and about 88%, or between about 20% and about 60%, or between about 20% and about 55%, or between about 20% and about 50%, or between about 20% and about 45%, or between about 20% and about 40%, or between about 25% and about 60%, or between about 25% and about 55%, or between about 25% and about 50%, or between about 25% and about 45%, or between about 25% and about 40%;and (iv) the percentage of cells in the population that express podocin can be at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, or at least about 98%.
[0052] In methods for identifying an enriched heterogeneous renal cell population as having therapeutic potential by determining whether the cells of the enriched heterogeneous renal cell population express SIX2, OSR1, RET, and podocin, the method can further determine whether the cells of the enriched heterogeneous renal cell population express one or more of LHX1, FGF8, RACK-1, and nephrin. In these methods, the enriched heterogeneous renal cell population can be identified as having therapeutic potential when the cells of the enriched heterogeneous renal cell population are determined to express SIX2, OSR, RET, and podocin, and are further determined to express one or more of LHX1, FGF8, RACK-1, and nephrin.
[0053] In these methods, the determination of whether the cells of the enriched heterogeneous renal cell population express SIX2, OSR1, RET, and podocin, and the further determination of whether the cells of the enriched heterogeneous renal cell population express one or more of LHX1, FGF8, RACK-1, and nephrin can be a determination of whether the cells of the enriched heterogeneous renal cell population express any of the following: SIX2, OSR1, RET, podocin, and LHX1, or SIX2, OSR1, RET, podocin, and FGF8, or SIX2, OSR1, RET, podocin, and RACK-1, or SIX2, OSR1, RET, podocin, and nephrin, or SIX2, OSR1, RET, podocin, LHX1, and FGF8, or SIX2, OSR1, RET, podocin, LHX1, and RACK-1. ACK-1, or SIX2, OSR1, RET, podocin, LHX1, and nephrin, or SIX2, OSR1, RET, podocin, FGF8, and RACK-1, or SIX2, OSR1, RET, podocin, FGF8, and nephrin, or SIX2, OSR1, RET, podocin, RACK-1, and nephrin, or SIX2, OSR1, RET, podocin, LHX1, and FGF 8, and RACK-1, or SIX2, OSR1, RET, podocin, LHX1, FGF8, and nephrin, or SIX2, OSR1, RET, podocin, LHX, RACK-1, and nephrin, or SIX2, OSR1, RET, podocin, FGF8, RACK-1, and nephrin, or SIX2, OSR1, RET, podocin, LHX, FGF8, RACK-1, and nephrin.
[0054] Determining whether cells of an enriched heterogeneous renal cell population express SIX2, OSR1, RET, and podocin, and further express one or more of LHX1, FGF8, RACK-1, and nephrin can be a determination of the percentage of cells that express SIX2, OSR1, RET, podocin, and further express one or more of LHX1, FGF8, RACK-1, and nephrin. When cells of an enriched heterogeneous kidney cell population are determined to express SIX2, OSR1, RET, and podocin, and further express one or more of LHX1, FGF8, and RACK-1, (i) the percentage of cells of the population that express SIX2 can be greater than 0% and up to about 15%, or greater than 0% and up to about 10.0%, or greater than 0% and up to about 9.5%, or greater than 0% and up to about 9.0%, or greater than 0% and up to about 8.5%, or greater than 0% and up to about at most about 8.0%, or greater than 0% to at most about 7.5%, or greater than 0% to at most about 7.0%, or greater than 0% to at most about 6.5%, or greater than 0% to at most about 6.0%, or between about 0.02% and about 15.0%, or between about 0.02% and about 10.0%, or between about 0.02% and about 9.0%, or between about 0.02% and about 8.0%, or between about 0.02% and about 7.0%, or between about 0.02% and about 6.0%, or between about 0.04% and about 15%, or between about 0.04% and about 10.0%, or between about 0.04% and about 9.0%, or between about 0.04% and about 8.0%, or between about 0.04% and about 7.0%, or between about 0.04% and about 6.0%, or between about 1.0% and about 15.0%, or between about 1.0% and about 10.0%, or between about 1.0% and about 9.0%, or between about 1.0% and about 8.0%, or between about 1.0% and about 7.0%, or between about 1.0% and about 6.0%, and (ii) produces an OSR1. The percentage of cells in the population that appear is greater than 0% to at most about 90%, or greater than 0% to at most about 88%, or greater than 0% to at most about 86%, or greater than 0% to at most about 84%, or greater than 0% to at most about 82%, or greater than 0% to at most about 80%, or greater than 0% to at most about 75%, or greater than 0% to at most about 70%, between about 30% and about 90%, or between about 30% and about 88%, or between about 30% and about 86%, or between about 30% and about 84%,or between about 30% and about 82%, or between about 30% and about 80%, or between 34% and 90%, or between about 34% and about 88%, or between about 34% and about 86%, or between about 34% and about 84%, or between about 34% and about 82%, or between about 34% and about 80%, or between about 36% and about 90%, or between about 36% and about 88%, or between about 36% and about 86%, or between about 36% and about 84%, or between about 36% and about 82%, or between about 36% and about 80%, or between about 40% and about 90%, or between about 40% and about 85%, or between about 45% and about 90%. 0%, or between about 45% and about 85%, or between about 50% and about 90%, or between about 50% and about 85%, or between about 55% and about 90%, or between about 55% and about 85%, or between about 60% and about 90%, or between about 60% and about 85%, or between about 65% and about 90%, or between about 65% and about 85%, or between about 70% and about 90%, or between about 70% and about 85%, and (iii) the percentage of cells in the population that express RET can be greater than 0% and at most about 94%, or greater than 0% and at most about 93%, or greater than 0% and at most about 92%. or from greater than 0% to at most about 91%, or from greater than 0% to at most about 90%, or from greater than 0% to at most about 89%, or from greater than 0% to at most about 88%, or from greater than 0% to at most about 87%, or from greater than 0% to at most about 86%, or from greater than 0% to at most about 85%, or between about 45% and about 95%, or between about 45% and about 94%, or between about 45% and about 93%, or between about 45% and about 92%, or between about 45% and about 91%, or between about 45% and about 90%, or between about 45% and about 89%, or between about 45% and about 88%, or about 47% between about 47% and about 94%, or between about 47% and about 93%, or between about 47% and about 92%, or between about 47% and about 91%, or between about 47% and about 90%, or between about 47% and about 89%, or between about 47% and about 88%, or between about 49% and about 95%, or between about 49% and about 94%, or between about 49% and about 93%, or between about 49% and about 92%, or between about 49% and about 91%, or between about 49% and about 90%, or between about 49% and about 89%, or between about 49% and about 88%, or between about 20% and about 60%or between about 20% and about 55%, or between about 20% and about 50%, or between about 20% and about 45%, or between about 20% and about 40%, or between about 25% and about 60%, or between about 25% and about 55%, or between about 25% and about 50%, or between about 25% and about 45%, or between about 25% and about 40%, and (iv) the percentage of cells in the population that express podocin is at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%. , at least about 96%, or at least about 98%, and optionally (v) the percentage of cells in the population that express LHX1 is at least about 5%, at least about 6%, or at least about 7%, or at least about 8%, or at least about 9%, or at least about 10%, greater than 0% to at most about 80%, or greater than 0% to at most about 70%, or greater than 0% to at most about 65%, or greater than 0% to at most about 64%, or greater than 0% to at most about 63%, or greater than 0% to at most about 62%, or greater than 0% to at most about 61%, or greater than 0% to at most up to about 60%, or from greater than 0% to at most about 59%, or from greater than 0% to at most about 58%, or from greater than 0% to at most about 57%, or from greater than 0% to at most about 56%, or from greater than 0% to at most about 55%, between about 6% and about 60%, or between about 6% and about 59%, or between about 6% and about 58%, or between about 6% and about 57%, or between about 6% and about 56%, or between about 6% and about 55%, or between about 6% and about 54%, or between about 8% and about 60%, or between about 8% and about 59%, or between about 8% and about 58%, or between about 8% and about 57%, or about % to about 56%, or between about 8% and about 55%, or between about 8% and about 54%, or between about 10% and about 60%, or between about 10% and about 59%, or between about 10% and about 58%, or between about 10% and about 57%, or between about 10% and about 56%, or between about 10% and about 55%, or between about 10% and about 54%, or between about 16% and about 80%, or between about 16% and about 70%, or between about 16% and about 60%, or between about 16% and about 58%, or between about 16% and about 56%, or between about 16% and about 54%, or between about 16% and about 52%,or between about 16% and about 50%, or between 22% and about 60%, or between about 22% and about 58%, or between about 22% and about 56%, or between about 22% and about 54%, or between about 22% and about 52%, or between about 22% and about 50%, and optionally (vi) the percentage of cells in the population that express FGF8 is at least about 0.2%, at least about 0.45%, or at least about 0.48%, or at least about 0.5%, or at least about 0.55%, or at least about 0.6%, or at least about 0.8%, or at least about 1.0%, or less. at most about 1.5%, or at least about 2.0%, or about 2.5%, greater than 0% to at most about 65%, or greater than 0% to at most about 64%, or greater than 0% to at most about 63%, or greater than 0% to at most about 62%, or greater than 0% to at most about 61%, or greater than 0% to at most about 60%, or greater than 0% to at most about 59% or at most about 58%, or greater than 0% to at most about 57%, or greater than 0% to at most about 56%, or greater than 0% to at most about 55%, between about 0.3% and about 64%, or between about 0.3% and about 63%, or between about 0.3% and about 64% between about 0.3% and about 62%, or between about 0.3% and about 61%, or between about 0.3% and about 60%, or between about 0.3% and about 59%, or between about 0.3% and about 58%, or between about 0.3% and about 57%, or between about 0.4% and about 64%, or between about 0.4% and about 63%, or between about 0.4% and about 62%, or between about 0.4% and about 61%, or between about 0.4% and about 60%, or between about 0.4% and about 59%, or between about 0.4% and about 58%, or between about 0.4% and about 57%, or between about 0.5% and about 64%, or between about 0.5% and about 63%, or between about 0.5% and about 62%, or between about 0.5% and about 61%, or between about 0.5% and about 60%, or between about 0.5% and about 59%, or between about 0.5% and about 58%, or between about 0.5% and about 57%, or between about 1% and about 64%, or between about 1% and about 54%, or between about 1% and about 44%, or between about 1% and about 34%, or between 1% and about 24%, or between about 2% and about 64%, or between about 2% and about 54%, or between about 2% and about 44%, or between about 2% and about 34%, or between 2% and about 24%, or between about 3% and about 64%;or between about 3% and about 54%, or between about 3% and about 44%, or between about 3% and about 34%, or between 3% and about 24%, and optionally (vii) the percentage of cells in the population that express RACK-I can be at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, or at least about 98%, and optionally (viii) the percentage of cells in the population that express nephron can be at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, between about 4% and about 95%, or between about 10% and about 95%, or between about 15% and about 95%, or between about 20% and about 95%, or between about 25% and about 95%, and between about 30% and about 95% The percentage may be between about 35% and about 95%, about 40% and about 95%, about 45% and 95%, about 50% and about 95%, about 55% and about 95%, about 60% and about 95%, about 65% and about 95%, about 70% and about 95%, about 75% and about 95%, about 80% and about 95%, or about 85% and about 95%.
[0055] In some other methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, it can be determined whether the cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1. In such methods, if it is determined that the cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1, the enriched heterogeneous renal cell population can be identified as having therapeutic potential.
[0056] Determining that the cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1 can include determining the percentage of cells of the enriched heterogeneous renal cell population that express nephrin, podocin, and LHX1. When the determining includes determining the percentage of cells of the enriched heterogeneous renal cell population that express nephrin, podocin, and LHX1 and then identifying the enriched heterogeneous renal cell population as having therapeutic potential, (i) the percentage of cells of the population that express nephrin can be at least about 70%, at least about 72%, at least about 75%, at least about 77%, at least about 80%, at least about 82%, at least about 85%, at least about 87%, at least about 90%, at least about 92%, at least about 95%, or at least about 97%, and (ii) the percentage of cells of the population that express podocin can be at least about 80%, at least about 82%, at least about 97%, or at least about 97%. and (iii) the percentage of cells in the population that express LHX1 can be at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, between about 15% and about 80%, between about 20% and about 80%, between about 15% and about 75%, between about 15% and about 70%, or between about 20% and about 80%.
[0057] In methods for identifying an enriched heterogeneous renal cell population as having therapeutic potential by determining whether the cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1, the method can further determine whether the cells of the enriched heterogeneous renal cell population express one or more of the nephrogenic markers SIX2, OSR1, RET, or FGF8. In these methods, the enriched heterogeneous renal cell population can be identified as having therapeutic potential when the cells of the enriched heterogeneous renal cell population are determined to express nephrin, podocin, and LHX1, and are further determined to express one or more of SIX2, OSR1, RET, or FGF8.
[0058] In these methods, determining whether cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1 and further express one or more of SIX2, OSR1, RET, or FGF8 can be determining whether cells of the enriched heterogeneous renal cell population express any of the following: nephrin, podocin, LHX1, and SIX2; nephrin, podocin, LHX1, and OSR1; nephrin, podocin, LHX1, and RET; nephrin, podocin, LHX1, and FGF8; nephrin, podocin, LHX1, SIX2, and OSR1; nephrin, podocin, LHX1, SIX2, and RET. T, nephrin, podocin, LHX1, SIX2, and FGF8, nephrin, podocin, LHX1, OSR1, and RET, nephrin, podocin, LHX1, ORS1, and FGF8, nephrin, podocin, LHX1, RET, and FGF8, nephrin, podocin, LHX1, SIX2, OSR1, and RET, nephrin, podocin, LHX1, SIX2, RET, and FGF8, nephrin, podocin, LHX1, OSR1, RET, and FGF8, nephrin, podocin, LHX1, SIX2, OSR1, and FGF8, or nephrin, podocin, LHX1, SIX2, OSR1, RET, and FGF8.
[0059] Determining whether cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1, and further express one or more of SIX2, OSR1, RET, and FGF8 can be determining the percentage of cells that express nephrin, podocin, and LHX1, and further express one or more of SIX2, OSR1, RET, and FGF8. The percentage of cells in the population that express nephrin, podocin, and LHX1, and one or more of SIX2, OSR1, RET, and FGF8 is determined, and the enriched heterogeneous renal cell population is then identified as having therapeutic potential if: (i) the percentage of cells that express nephrin is at least about 70%, at least about 72%, at least about 75%, at least about 77%, at least about 80%, at least about 82%, at least about 85%, at least about 87%, (ii) the percentage of cells expressing podocin may be at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, or at least about 98%; and (iii) the percentage of cells expressing LHX1 may be at least about 15%. %, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, between about 15% and about 80%, between about 20% and about 80%, between about 15% and about 75%, between about 15% and about 70%, or between about 20% and about 80%, and optionally (iv) the percentage of cells expressing SIX2 is 0 % to at most about 15.0%, or greater than 0% to at most about 13%, or greater than 0% to at most about 11%, or greater than 0% to at most about 9%, or greater than 0% to at most about 7%, or greater than 0% to at most about 5%, or greater than 0% to at most about 3%, or between about 0.02% and about 15%, or between about 0.02% and about 13%, or between about 0.02% and about 11%, or between about 0.02% and about 9%, or between about 0.02% and about 7%, or between about 0.02% and about 5%;or between about 0.02% and about 3%, or between about 0.04% and about 15%, or between about 0.04% and about 13%, or between about 0.04% and about 11%, or between about 0.04% and about 9%, or between about 0.04% and about 7%, or between about 0.04% and about 5%, or between about 0.04% and about 3%, or between about 1% and about 15%, or between about 1% and about 13%, or between about 1% and about 11%, or between about 1% and about 9%, or between about 1% and about 7%, or between about 1% and about 5%, or between about 1% and about 3%, and optionally (v) the population of cells expressing OSR1. The percentage may be greater than 0% to at most about 90%, or greater than 0% to at most about 88%, or greater than 0% to at most about 86%, or greater than 0% to at most about 84%, or greater than 0% to at most about 82%, or greater than 0% to at most about 80%, or greater than 0% to at most about 75%, or greater than 0% to at most about 70%, between about 30% and about 90%, or between about 30% and about 88%, or between about 30% and about 86%, or between about 30% and about 84%, or between about 30% and about 82%, or between about 30% and about 80%, or between 34% and 90%, or between about 34% and between about 34% and about 86%, or between about 34% and about 84%, or between about 34% and about 82%, or between about 34% and about 80%, or between about 36% and about 90%, or between about 36% and about 88%, or between about 36% and about 86%, or between about 36% and about 84%, or between about 36% and about 82%, or between about 36% and about 80%, or between about 40% and about 90%, or between about 40% and about 85%, or between about 45% and about 90%, or between about 45% and about 85%, or between about 50% and about 90%, or between about 50% and about 85%, or between about 55% and about 90%, or between about 55% and about 85%, or between about 60% and about 90%, or between about 60% and about 85%, or between about 65% and about 90%, or between about 65% and about 85%, or between about 70% and about 90%, or between about 70% and about 85%, and optionally (vi) the percentage of cells expressing RET is greater than 0% up to at most about 94%, or greater than 0% up to at most about 93%, or greater than 0% up to at most about 92%, or greater than 0% up to at most about 91%, or greater than 0% up to at most about 90%, or greater than 0% up to at most about 89%;or from greater than 0% to at most about 88%, or from greater than 0% to at most about 87%, or from greater than 0% to at most about 86%, or from greater than 0% to at most about 85%, or between about 45% and about 95%, or between about 45% and about 94%, or between about 45% and about 93%, or between about 45% and about 92%, or between about 45% and about 91%, or between about 45% and about 90%, or between about 45% and about 89%, or between about 45% and about 88%, or between about 47% and about 95%, or between about 47% and about 94%, or between about 47% and about 93%, or between about 47% and about 92%; or between about 47% and about 91%, or between about 47% and about 90%, or between about 47% and about 89%, or between about 47% and about 88%, or between about 49% and about 95%, or between about 49% and about 94%, or between about 49% and about 93%, or between about 49% and about 92%, or between about 49% and about 91%, or between about 49% and about 90%, or between about 49% and about 89%, or between about 49% and about 88%, or between about 20% and about 60%, or between about 20% and about 55%, or between about 20% and about 50%, or between about 20% and about 45%, or between about 20% and about 60%. or between about 40%, or between about 25% and about 60%, or between about 25% and about 55%, or between about 25% and about 50%, or between about 25% and about 45%, or between about 25% and about 40%, and optionally (vii) the percentage of cells expressing FGF8 is at least about 0.2%, at least about 0.45%, or at least about 0.48%, or at least about 0.5%, or at least about 0.55%, or at least about 0.6%, or at least about 0.8%, or at least about 1.0%, or at least about 1.5%, or at least about 2.0%, or less. at most about 2.5%, from greater than 0% to at most about 65%, or from greater than 0% to at most about 60%, or from greater than 0% to at most about 59% or at most about 58%, or from greater than 0% to at most about 57%, or from greater than 0% to at most about 56%, or from greater than 0% to at most about 55%, between about 0.3% and about 64%, or between about 0.3% and about 63%, or between about 0.3% and about 62%, or between about 0.3% and about 61%, or between about 0.3% and about 60%, or between about 0.3% and about 59%, or between about 0.3% and about 58%, or between about 0.3% and about 57%;or between about 0.4% and about 64%, or between about 0.4% and about 63%, or between about 0.4% and about 62%, or between about 0.4% and about 61%, or between about 0.4% and about 60%, or between about 0.4% and about 59%, or between about 0.4% and about 58%, or between about 0.4% and about 57%, or between about 0.5% and about 64%, or between about 0.5% and about 63%, or between about 0.5% and about 62%, or between about 0.5% and about 61%, or between about 0.5% and about 60%, or between about 0.5% and about 59%, or between about 0.5% and about 58%, or between about 0.5% and about 57%, or between about 1% and about 64%, or between about 1% and about 54%, or between about 1% and about 44%, or between about 1% and about 34%, or between 1% and about 24%, or between about 2% and about 64%, or between about 2% and about 54%, or between about 2% and about 44%, or between about 2% and about 34%, or between 2% and about 24%, or between about 3% and about 64%, or between about 3% and about 54%, or between about 3% and about 44%, or between about 3% and about 34%, or between 3% and about 24%.
[0060] In methods for identifying an enriched heterogeneous renal cell population as having therapeutic potential by determining whether the cells of the enriched heterogeneous renal cell population express nephrin, podocin, and LHX1, in addition to or instead of determining whether the cells of the enriched heterogeneous renal cell population express one or more of the nephrogenic markers SIX2, OSR1, RET, or FGF8, it can be further determined whether the cells express RACK1. In these methods, an enriched heterogeneous renal cell population can be identified as having therapeutic potential if the cells of the heterogeneous renal cell population express nephrin, podocin, and LHX1 and also express RACK-1.
[0061] In these methods, determining whether cells of the enriched heterogeneous renal cell population express RACK1 can be a determination of the percentage of cells that express RACK1 in addition to the percentage of cells of the enriched heterogeneous renal cell population that express nephrin, podocin, and LHX1, and optionally the percentage of cells that express one or more of SIX1, OSR1, RET, and FGF8. When the percentage of cells of the enriched heterogeneous renal cell population that express RACK1 is determined as part of the above methods, the percentage that identifies the enriched renal cell population as having therapeutic potential can be at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, or at least about 98%.
[0062] In yet another method of identifying an enriched heterogeneous renal cell population as having therapeutic potential, it can be determined whether the cells of the enriched heterogeneous renal cell population express gamma-glutamyl transpeptidase (GGT)-1, CK18, and podocin. In such a method, if it is determined that the cells of the enriched heterogeneous renal cell population express GGT-1, CK18, and podocin, the enriched heterogeneous renal cell population can be identified as having therapeutic potential. Determining that the cells of the enriched heterogeneous renal cell population express GGT-1, CK18, and podocin can include determining the percentage of cells of the enriched heterogeneous renal cell population that express GGT-1, CK18, and podocin. When the cells of the enriched heterogeneous renal cell population are determined to express GGT-1, CK18, and podocin, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if (i) at least 4.5%, or at least 10%, or at least 18% of the cells of the population express GGT-1, (ii) at least 80% of the cells of the population express CK18, and (iii) at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, or at least about 98% of the cells of the population express podocin. In these methods, VEGF and / or KIM-1 secreted into the cell culture medium by the cells of the population can further identify the cells as having therapeutic potential.
[0063] In some methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, it is not necessary to determine whether the cells of the enriched heterogeneous renal cell population express at least one nephrogenic marker. In these alternative methods of identifying an enriched heterogeneous renal cell population as having therapeutic potential, the cells can be identified as having therapeutic potential by determining the expression level of one or more of the following genes: RHAMM, C2, C3, C4, fibrinogen, coagulation factor XIII, TEK, KDR, Notch1, Notch3, Timp3, Vwf, Adam15, Gas6, Igfbp1, or Tm4sf4. In these alternative methods, the one or more genes whose expression level can be determined can be RHAMM. In these alternative methods, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if the determined expression level of one or more genes by the cells of the enriched heterogeneous renal cell population is increased compared to the expression of one or more genes by cells of a control renal cell population.
[0064] Additionally, in any of the methods for identifying an enriched heterogeneous renal cell population as having therapeutic potential, the enriched heterogeneous renal cell population can be further subjected to transcriptional or transcriptome signature analysis. When the enriched heterogeneous renal cell population is subjected to transcriptional or transcriptome signature analysis, the enriched heterogeneous renal cell population can be identified as having therapeutic potential if it is determined that the cells of the enriched heterogeneous renal cell population are upregulated in a transcriptional pathway or signature associated with complement or the complement cascade, vascular development, vascular morphogenesis, vasculature development, or response to wounding, and / or downregulated in a transcriptional pathway or signature associated with extracellular matrix-receptor interactions.
[0065] The markers discussed herein that are useful for identifying enriched heterogeneous renal cell populations as having therapeutic potential, such as SIX2, OSR1, RET, LHX1, FGF8, nephrin, podocin, and RACK-1, can also be useful in methods for identifying whether a patient in need of treatment with an enriched heterogeneous renal cell population, such as a patient in need of treatment for a kidney disease, tubular transport defect, or glomerular filtration defect, is an intermediate to high responder or a low responder to treatment. In such methods, if a patient is identified as an intermediate to high responder, the patient can be distinguished from patients whose response to treatment may be an increase in estimated glomerular filtration rate (eGFR). If a patient is identified as a low responder, the patient can be distinguished from patients whose response to treatment may be an improvement in the slope of eGFR but not an increase in eGFR. To identify whether a patient may be an intermediate-high or low responder, the percentage of cells in the enriched heterogeneous renal cell population that express one or more markers, such as SIX2, OSR1, RET, LHX1, FGF8, nephrin, podocin, and RACK-1, can be determined. For example, to identify whether a patient is an intermediate-high or low responder, the percentage of cells in the enriched heterogeneous renal cell population that express LHX1 can be determined. If the percentage of cells in the heterogeneous renal cell population that express LHX1 is determined to be at least 50%, the patient can be identified as an intermediate-high or low responder. If the percentage of cells in the heterogeneous renal cell population that express LHX1 is determined to be less than 50%, the patient can be identified as a low responder. As another example, to identify whether a patient is an intermediate-high or low responder, the percentage of cells in the enriched heterogeneous renal cell population that express SIX2 can be determined. If the percentage of cells in the heterogeneous renal cell population that express SIX2 is determined to be at least 3.5%, the patient can be identified as an intermediate to good responder.If the percentage of cells in the heterogeneous renal cell population that express SIX2 is determined to be less than 3.5% but greater than 0%, the patient can be identified as a poor responder. The percentages of both LHX1 and SIX2 can be determined to identify the patient as an intermediate-to-good responder or a poor responder.
[0066] In any of the methods for identifying an enriched heterogeneous renal cell population as having therapeutic potential, determining whether the cells of the enriched heterogeneous renal cell population express one or more, e.g., nephrogenic markers and / or additional markers (or determining the expression level of one or more genes) can be determining whether the cells of the enriched heterogeneous renal cell population express the markers in the form of nucleic acids, e.g., mRNA or miRNA, or polypeptides (or determining the expression level of one or more genes). The markers (or genes whose expression or expression level is determined) can be membrane-bound or membrane-associated, intracellular, or secreted from the cells. The expression of one or more, e.g., nephrogenic markers and / or additional markers (or the expression level of genes) by the cells of the enriched heterogeneous renal cell population can be determined via any assay suitable for detecting the presence of the markers (or the expression level of genes). Many such assays are known in the art. For example, when the expression level of a marker (or gene is determined and its expression) is determined in the form of a polypeptide, it can be determined by an assay such as Western blot, fluorescence-activated cell sorting (FACS), enzyme-linked immunosorbent assay (ELISA), etc. When the expression level of a marker (or gene is determined and its expression) is determined in the form of a nucleic acid, it can be determined by an assay such as Southern blot, polymerase chain reaction (PCR) or reverse transcriptase PCR, sequence analysis of gene expression (SAGE), mass array, or fluorescence in situ hybridization (FISH). Regardless of whether the assay determines whether a nephrogenic marker and / or additional markers are expressed by cells of an enriched heterogeneous renal cell population (or determines the expression level of one or more genes), the assay can include a labeled detection reagent that determines whether the marker (or gene whose expression level is determined) is present and / or determines the percentage of cells expressing the marker (or gene). The labeled detection reagent can include (i) a moiety that directly or indirectly forms a complex with the marker (or expression product of the gene), and (ii) a detection moiety.Non-limiting detection moieties include radioisotopes, eg, . 35 S, 14 C. 125 I, 3 H, and 131 I, colloidal gold particles, fluorescent labels such as Texas Red, rhodamine, fluorescein, dansyl, lissamine, phycocryterin, phycocyanin, SPECTRUM ORANGE, SPECTRUM GREEN1, and enzyme substrates such as firefly luciferase, bacterial luciferase, luciferin, horseradish peroxidase, alkaline phosphatase, or β-galactosidase.
[0067] Enriched heterogeneous renal cell populations that may be identified as having therapeutic potential in any of the above methods may be enriched for one or more renal cell types, such as renal epithelial cells, renal tubular cells, renal tubular epithelial cells, or renal proximal tubule cells. The enrichment of these enriched heterogeneous renal cell populations for one or more renal cell types may refer to an enriched heterogeneous renal cell population having a higher percentage of one or more renal cell types than a patient's kidney tissue, a patient's kidney biopsy, or an in vitro culture of cells established from a patient's kidney tissue or kidney biopsy (which may be collectively referred to as a "starting renal cell population"). When the starting renal cell population is a patient's kidney tissue or an in vitro culture of cells established from a patient's kidney tissue or kidney biopsy, it may be a renal cell preparation that includes dissociated cells of kidney tissue or kidney biopsy (e.g., cells dissociated from kidney tissue or kidney biopsy via mincing and / or enzymatic digestion), which may or may not have been processed to remove red blood cells and debris. An example of an enriched heterogeneous renal cell population is the selected renal cell population (SRC) described in the Examples herein.
[0068] The enriched heterogeneous renal cell population may be enriched for one or more renal cell types as a result of being prepared via a method that includes a separation step from a starting renal cell population (e.g., a patient's kidney tissue, a patient's kidney biopsy, or an in vitro culture of cells established from the patient's kidney tissue or kidney biopsy). The separation step can be a step of separating cells of the starting renal cell population that have not been passaged more than one, two, or three times based on their buoyant density. When the separation step is a step of separating cells based on their buoyant density, the separation step can utilize a single- or multi-step continuous or discontinuous density gradient using a density gradient medium such as glycerol, glucose, OptiPrep, Percoll, or Ficoll-Paque. As a result of this use of such a density gradient medium, the cells of the starting renal cell population (or a starting renal cell population that has been passaged at most one, two, or three times) can be separated into one or more distinct fractions from which the cells of the enriched heterogeneous renal cell population can be clearly identified and isolated. The distinguishable fraction(s) can be fractions in which the buoyant density of cells in the fraction(s) is greater than about 1.045 g / mL, or greater than 1.045 g / mL, or 1.045 g / mL or greater. The distinguishable fraction(s) can be fractions in which the buoyant density of cells in the fraction(s) is greater than about 1.04 g / mL, or greater than 1.04 g / mL, or 1.04 g / mL or greater, or greater than about 1.0419 g / mL, or greater than 1.0419 g / mL, or 1.0419 g / mL or greater. The distinguishable fraction(s) can be fractions in which the buoyant density is between about 1.045 g / mL and about 1.091 g / mL, or between about 1.045 g / mL and about 1.052 g / mL. Alternatively, the separating step can be a step of separating cells of the starting renal cell population (or cells of the starting renal cell population that have not been passaged more than one, two, or three times) based on whether they express a particular marker on their surface. When the separating step separates cells based on the expression of their particular cell surface marker, the separating step can be a step that utilizes flow cytometry.Flow cytometry can sort cells from a starting renal cell population (or a starting renal cell population that has been passaged at most once, twice, or three times) if the starting renal cell population expresses a particular surface marker, such as nephrin, characteristic of renal epithelial cells, renal tubular cells, renal tubular epithelial cells, or renal proximal tubule cells, thereby forming an isolated, enriched, heterogeneous renal cell population.
[0069] An enriched heterogeneous renal cell population prepared from a starting renal cell population (or a starting renal cell population that has been passaged at most once, twice, or three times) can be cultured under hypoxic conditions prior to the separation step. When the cells are cultured under hypoxic conditions prior to the separation step, the cells can be cultured under conditions where the oxygen level is less than about 20%, or less than about 15%, or less than about 10%, or less than about 9%, or less than about 8%, or less than about 7%, or less than about 6%, or less than about 5% oxygen, or less than about 4% oxygen, or less than about 3% oxygen, or less than about 2% oxygen. When the cells are cultured under hypoxic conditions, the cells can be cultured under hypoxic conditions for at least 6 hours, at least 8 hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 16 hours, at least 20 hours, at least 24 hours, at least 30 hours, at least 36 hours, at least 42 hours, or at least 48 hours.
[0070] Generally, enriched heterogeneous renal cell populations can be prepared from any starting cell population, for example, an in vitro culture of cells established from a patient's kidney tissue or a patient's kidney biopsy. When an enriched heterogeneous renal cell population is prepared from an in vitro culture of cells established from a patient's kidney tissue or a kidney biopsy, the cells of the in vitro culture can be expanded by passage at most once, at most twice, or at most three times. Alternatively, if desired, the cells of the in vitro culture of cells established from kidney tissue or a kidney biopsy can be cryopreserved and then expanded by passage at most once, at most twice, or at most three times. Once the cells are expanded, the expanded cells can be cryopreserved. The expanded cells, whether cryopreserved or not, can then be subjected to a separation process, or can be subjected to hypoxic culture conditions followed by a separation process. The enriched heterogeneous renal cell population can be isolated by performing a separation process. Once the enriched renal cell population is isolated, it can be frozen and / or analyzed before being used as a therapeutic agent.
[0071] Furthermore, one or more control renal cell populations can be generated in the preparation of an enriched heterogeneous renal cell population from a starting renal cell population. The control renal cell population can be any renal cell population generated as a result of subjecting the starting renal cell population to one or more steps or conditions prior to the separation step in the preparation of an enriched heterogeneous renal cell population. The control renal cell population can be a renal cell population generated from the starting renal cell population after subjecting the starting renal cell population to an expansion step, for example, by passage the starting renal cell population at most one, two, or three times prior to the separation step. Alternatively, the control renal cell population can be a renal cell population generated from the starting renal cell population after culturing the starting renal cell population under hypoxic conditions prior to the separation step. In another example, the control renal cell population can be a renal cell population generated from the starting renal cell population as a result of passage the starting renal cell population at most one, two, or three times and culturing the starting renal cell population under hypoxic conditions prior to the separation step. In yet another example, the control renal cell population can be a renal cell population generated from a starting renal cell population as a result of expanding the starting renal cell population by at most one, two, or three passages, and / or culturing under hypoxic conditions, and / or cryopreserving the starting renal cell population prior to performing the separation step. The control renal cell population can be a renal cell population generated from a starting renal cell population that has been subjected to a complete series of steps or conditions in preparation for performing the separation step, but has not yet been subjected to the separation step.
[0072] Such control renal cell populations can be used in the methods provided herein, where an enriched heterogeneous renal cell population can be identified as having therapeutic potential if the expression level of one or more genes, e.g., RHAMM, C2, C3, C4, fibrinogen, coagulation factor XIII, TEK, KDR, Notch1, Notch3, Timp3, Vwf, Adam15, Gas6, Igfbp1, or Tm4sf4, by cells of the enriched heterogeneous renal cell population is increased compared to the expression level of one or more genes by cells of the control renal cell population. The increase in the level of expression of one or more genes can be an increase of at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%. In such methods, the one or more genes can be or can include RHAMM, and the increase in RHAMM expression levels in the enriched heterogeneous kidney cell population compared to the control population can be at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%. In such methods, the increase in expression levels can be an increase in the percentage of cells expressing the one or more genes, or an increase in the total expression (adjusted for cell number) of the one or more genes.
[0073] When an enriched heterogeneous renal cell population is identified as having therapeutic potential according to any of the methods disclosed herein, the cell population can be included in a pharmaceutical composition, or can be administered in a method of treating kidney disease in a patient in need of treatment, and / or can be used in the manufacture of a medicament for treating kidney disease. When an enriched heterogeneous renal cell population is identified as having therapeutic potential and included in a pharmaceutical composition, the cell population can be formulated as a hydrogel composition or a liquid composition. The composition may or may not include hyaluronic acid.
[0074] When the pharmaceutical composition is formulated as a hydrogel composition, the cells of the enriched heterogeneous renal cell composition can be combined with a temperature-sensitive cell-stabilizing biomaterial that maintains a gel state at about 8°C or below, maintains a substantially liquid state at about ambient temperature or above, and is in a solid-liquid transition state between about 8°C and about ambient temperature or above. The temperature-sensitive cell-stabilizing biomaterial included in the hydrogel composition can be one or more of a recombinant extracellular matrix protein, an extracellular matrix derived from the kidney or another tissue or organ, or gelatin. When the temperature-sensitive cell-stabilizing biomaterial includes gelatin, the gelatin can be derived from type I alpha I collagen, such as porcine type I alpha I collagen or recombinant human type I alpha I collagen. When the temperature-sensitive cell-stabilizing biomaterial includes gelatin, the gelatin can be present in the pharmaceutical composition at about 0.5% to about 1% (weight / volume), or about 0.8% to about 0.9% (weight / volume), or about 0.88% (weight / volume). The cells of the enriched heterogeneous renal cell population may be dispersed throughout the biomaterial or may be substantially uniformly distributed throughout the biomaterial.
[0075] When the pharmaceutical composition is formulated as a liquid composition, the enriched heterogeneous renal cell population can be combined with any suitable liquid, such as an appropriate cell storage or cell culture medium, saline, or a combination thereof, and used immediately or stored frozen until it is time to use it.
[0076] If the enriched heterogeneous renal cell population is identified as having therapeutic potential, the enriched heterogeneous renal cell population or a pharmaceutical composition comprising the enriched heterogeneous renal cell population can be administered to a patient in a method for treating kidney disease. If the enriched heterogeneous renal cell population is identified as having therapeutic potential, the enriched heterogeneous renal cell population or a pharmaceutical composition comprising the enriched heterogeneous renal cell population can be used in the manufacture of a medicament for treating kidney disease. The kidney disease can be any stage or degree of acute or chronic renal failure. The kidney disease can originate in the kidney or can be secondary to another condition, such as heart failure, hypertension, diabetes, autoimmune disease, or liver disease. Alternatively, the kidney disease can result from acute damage to the kidney or from abnormalities in the kidney and / or urinary tract. The kidney disease can further include endocrine dysfunction, such as anemia, e.g., erythropoietin deficiency, and mineral imbalance, e.g., vitamin D deficiency.
[0077] If an enriched heterogeneous renal cell population is identified as having therapeutic potential, the enriched heterogeneous renal cell population or a pharmaceutical composition comprising the enriched heterogeneous renal cell population can be administered to treat kidney disease. Kidney disease can be treated by restoring kidney function, stabilizing kidney function, improving kidney function, reducing renal fibrosis, reducing renal inflammation, and inducing kidney function in patients in need of such treatment. Treating kidney disease can restore mineral balance or alleviate anemia in patients in need of such treatment. Treating kidney disease can prolong or prevent the need for dialysis or prolong or prevent the need for a kidney transplant in patients in need of treatment for kidney disease. If treating kidney disease prolongs the patient's need for dialysis or kidney transplant, the prolongation can be at least 1 year, at least 1.5 years, at least 2 years, at least 2.5 years, at least 3 years, at least 3.5 years, at least 4 years, at least 4.5 years, at least 5 years, at least 5.5 years, at least 6 years, at least 6.5 years, at least 7 years, at least 7.5 years, at least 8 years, at least 8.5 years, at least 9 years, at least 9.5 years, or at least 10 years. Treatment of kidney disease can be determined by observing improvements in a patient's serum albumin, albumin to globulin ratio (A / G ratio), serum phosphorus, serum sodium, kidney size (which can be measured by ultrasound), serum calcium, phosphorus:calcium ratio, serum potassium, proteinuria, urinary creatinine, serum creatinine, blood nitrogen urea (BUN), cholesterol levels, triglyceride levels, and glomerular filtration rate (GFR), weight, blood pressure (mean systemic blood pressure, diastolic blood pressure, or systolic blood pressure), and physical endurance exercise capacity.
[0078] If an enriched heterogeneous renal cell population is identified as having therapeutic potential, the cell population can be administered to a patient by any appropriate route of administration known in the art. For example, the enriched heterogeneous renal cell population, or a pharmaceutical composition comprising the enriched heterogeneous renal cell population, can be administered systemically to a patient in need of treatment for kidney disease. The enriched heterogeneous renal cell population, or a pharmaceutical composition comprising the enriched heterogeneous renal cell population, can be administered to or within the kidney(s) of a patient in need of treatment for kidney disease. When the enriched heterogeneous renal cell population is administered to or within the kidney(s) of a patient in need of treatment for kidney disease, the cell population can be administered via single or multiple injections. The cell population can be administered via direct laparotomy, via direct laparoscopic surgery, transperitoneally, or percutaneously. The enriched heterogeneous renal cell population, or a pharmaceutical composition comprising the enriched heterogeneous renal cell population, can be administered by percutaneous injection into the renal cortex of the kidney, or by percutaneously inserting a guide cannula to puncture the kidney capsule and then injecting the enriched heterogeneous renal cell population into the kidney.
[0079] The enriched heterogeneous renal cell population or pharmaceutical composition comprising the enriched heterogeneous renal cell population is administered in a therapeutically effective dose by any suitable route. A therapeutically effective dose or therapeutically effective amount administered to a patient in need of treatment for kidney disease is about 1 x 10 per gram of the patient's estimated kidney weight. 6 pieces~9×10 6 The therapeutically effective amount of the pharmaceutical composition may comprise about 1 x 10 cells of the enriched heterogeneous kidney cell population per gram of estimated kidney weight in the patient. 6 Enriched heterogeneous kidney cell population cells, 1 x 10 6 Enriched heterogeneous kidney cell population cells, approximately 2 x 10 6 Enriched heterogeneous kidney cell population cells, 2 x 10 6 Enriched heterogeneous kidney cell population cells, approximately 3 x 10 6 3 x 10 cells of enriched heterogeneous kidney cell population 6Enriched heterogeneous kidney cell population cells, approximately 4 x 10 6 Enriched heterogeneous kidney cell population cells, 4 x 10 6 Enriched heterogeneous kidney cell population cells, approximately 5 x 10 6 cells of an enriched heterogeneous kidney cell population, or 5 x 10 6 The dose of cells of the enriched heterogeneous kidney cell population may be:
[0080] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein which equivalents are intended to be encompassed by the claims appended hereto.
[0081] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. [Example]
[0082] Example 1: Preparation of enriched heterogeneous kidney cell populations Solution. In one method for preparing enriched heterogeneous renal cell populations, enriched heterogeneous renal cell populations were prepared from kidney tissue or biopsy samples using the reagents shown in Table 1.
[0083] [Table 1]
[0084] Dulbecco's phosphate buffered saline (DPBS) is useful for all cell washing.
[0085] Isolation of cells from kidney samples. In this method, kidney tissue via kidney biopsy was used as the source material to arrive at a preparation of unenriched kidney cells. Generally, the kidney tissue used in the preparation can consist of one or more of cortical tissue, corticomedullary junction tissue, or medullary tissue. Corticomedullary junction tissue is preferred. From kidneys with CKD, multiple biopsy cores (a minimum of two) may be required to avoid scar tissue. Kidney tissue was obtained from patients by a clinician. If necessary, the tissue may be transported in tissue transport medium.
[0086] The tissue was washed with tissue wash solution to reduce the bioburden introduced and then processed to extract cells.
[0087] Renal tissue was minced and dissociated in digestion solution. The resulting cell suspension was neutralized, washed, and resuspended in Dulbecco's Modified Eagle Medium (D-MEM) + 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), washed, and resuspended in renal cell growth medium (RCGM). Cultures were initiated in tissue culture-treated polystyrene flasks or dishes in RCGM. For example, one biopsy was plated in one T25 Nunc flask in 8 mL of RCGM.
[0088] Expansion of unenriched heterogeneous kidney cultures. Renal cell expansion was dependent on the amount of tissue received and successful isolation of renal cells from the incoming tissue. Isolated cells can be cryopreserved if desired. Renal cell growth kinetics may vary from sample to sample due to inherent variability in cells isolated from individual patients.
[0089] A defined cell expansion process has been developed that accommodates the range of cell recovery due to variability in the incoming tissue. Table 2. Renal cell expansion required serial passaging using defined cell culture procedures in renal cell growth medium in closed culture vessels (e.g., T-flasks, Cell Factories, HyperStacks™).
[0090] [Table 2]
[0091] Once cell growth was observed in the first T-flask (passage 0) and no visible signs of contamination were observed, the culture medium was replaced, and then every 2–4 days thereafter. Cells were evaluated by visually observing the cultures under a microscope to verify kidney cell morphology. The cultures characteristically exhibited a dense pavement or cobblestone appearance due to the cells being densely packed together. These morphological features may change during expansion and may not be present at all passages. Cell culture confluence was estimated using an image library of cells at various levels of confluence in the culture vessels used throughout cell expansion.
[0092] Renal cells were passaged by trypsinization when the culture vessels reached at least 50% confluence. Detached cells were collected in a vessel containing renal cell growth medium, counted, and cell viability was calculated. At each cell passage, cells were cultured in a sufficient number of culture vessels to reach 500–4000 cells / cm. 2 Cells were seeded at 1000 kJ / well and expanded to the required cell number for therapeutic formulation or evaluation. The culture vessel was placed in a 37°C incubator with 5% CO2. Cell morphology and confluence were monitored as described above, and the tissue culture medium was changed every 2–4 days. Table 3 lists the viability of human kidney cells observed during cell isolation and expansion of kidney biopsies from human donors.
[0093] [Table 3]
[0094] The inherent variability of tissues from different patients may result in different cell yields in culture. Therefore, it is not practical to strictly prescribe the timing of cell passage or the number and type of culture vessels required to achieve the target cell number at each passage. Typically, kidney cells undergo two or three passages, but the culture period and cell yield may vary depending on the cell growth rate.
[0095] For harvesting or passaging, cells were detached using TrypLE (Invitrogen). Viability was assessed via trypan blue exclusion, and counts were performed manually using a hemocytometer, using the automated Cellometer™ counting system (Nexcelom Bioscience, Lawrence, MA), or using an NC-200 NucleoCounter with AO / DAPI.
[0096] Cryopreservation of Cultured Cells. Expanded renal cells can be cryopreserved to address the inherent variability of cell growth from individual patients and to deliver therapeutics, such as enriched heterogeneous renal cell populations, as needed, on a predetermined clinical schedule. Cryopreserved cells also provide a spare cell source in situations where a therapeutic / additional therapeutic dose is needed (e.g., additional doses in situations of patient illness delay, unanticipated course events, etc.). Conditions used to cryopreserve cells and recover viable, functional cells upon thawing have been established.
[0097] When expanded kidney cells are cryopreserved, the cells are stored in cryopreservation solution at approximately 50 x 10 cells per mL. 6 The cells were suspended and dispensed into vials at a final concentration of approximately 50 x 10 cells per mL. 6 A 1 ml vial containing cells was placed in the freezing chamber of a controlled rate freezer and frozen at a pre-programmed rate. After freezing, the cells were transferred to a liquid nitrogen freezer for in-process storage.
[0098] Preparation of Enriched Heterogeneous Renal Cell Populations. Enriched heterogeneous renal cell populations can be prepared from final culture vessels grown from cryopreserved cells or grown directly from expansion cultures.
[0099] For cryopreserved cells, the cells were thawed and plated into tissue culture vessels for one final expansion step. When the final culture vessels reached approximately 50%-100% confluence, the cells were ready for processing to isolate enriched heterogeneous kidney cell populations. A medium change and final wash with NKA diluted any remaining cryopreservation solution in the final product.
[0100] Once the final cell culture vessels reached at least 50% confluence, they were transferred to a hypoxic incubator set at 2% oxygen in a 5% CO environment at 37°C and cultured overnight. Cells can be maintained in an oxygen-controlled incubator set at 2% oxygen for less than 24 hours or overnight. Exposure to a more physiologically relevant hypoxic (2%) environment improved cell isolation efficiency and allowed for better detection of hypoxia-inducible markers such as VEGF.
[0101] After exposing the cells to hypoxic conditions for a sufficient period of time (overnight to 48 hours), the cells were detached using TrypLE (Invitrogen). Viability was assessed via trypan blue exclusion, and counting was performed manually using a hemocytometer, using an automated Cellometer™ counting system (Nexcelom Bioscience, Lawrence, MA), or using an NC-200 NucleoCounter with AO / DAPI. Cells were washed once with OptiMEM and counted at approximately 850 × 10 per mL in DPBS. 6 The cells were resuspended in 100 ml of PBS.
[0102] The harvested renal cell populations were separated based on cell buoyant density using centrifugation across a density boundary / interface. Renal cell suspensions were separated by centrifugation over a 7% iodixanol solution in OptiMEM (OptiPrep, 60% wt / vol).
[0103] A 7% OptiPrep density interface solution was prepared, and the refractive index, which indicates the desired density, was measured before use (refractive index 1.3456 ± 0.0004). Harvested kidney cells were layered on top of the solution. The density interface was centrifuged at 800 × g for 20 minutes (continuously) at room temperature in either a centrifuge tube or a cell processor (e.g., COBE 2991). Cell fractions exhibiting a buoyant density greater than approximately 1.045 g / mL were collected as a separate pellet after centrifugation. Cells maintaining a buoyant density less than 1.045 g / mL were excluded and discarded.
[0104] The pellet of enriched heterogeneous renal cell population was resuspended in DPBS. Carryover of residual OptiPrep, FBS, culture medium, and supplements in the final product was minimized by four DPBS washing steps.
[0105] Example 2: Identification and determination of nephrogenic marker expression by enriched heterogeneous kidney cell populations exhibiting therapeutic potential Introduction. Regeneration of complex tissues and organs, including the kidney, can utilize mechanistic elements common to development and organogenesis. The expression of multiple markers typically associated with the earliest signaling events during embryonic nephrogenesis indicates that enriched heterogeneous renal cell populations prepared, for example, via the process described in Example 1, have dedifferentiated and acquired more renal progenitor-like characteristics. Introduction of enriched heterogeneous renal cell populations with these traits into diseased renal parenchyma can trigger the initiation of key signaling cascades that normally mediate nephrogenesis but (in the context of adult parenchyma) can be interpreted as regeneration.
[0106] Methods. Enriched heterogeneous renal cell populations prepared, for example, as described in Example 1, were tested for expression of nephrogenic markers by FACS analysis. The antibodies used to detect nephrogenic marker expression on the cells are identified in Table 4.
[0107] [Table 4]
[0108] Cell preparation for FACS. To perform FACS analysis, cells from enriched heterogeneous renal cell populations were harvested by trypsin digestion and centrifuged at 400 g for 10 minutes to form a cell pellet. The cell pellet was washed twice with phosphate-buffered saline (PBS), resuspended, and fixed in 4% paraformaldehyde solution containing saponin for cell permeabilization, which is required for intracellular antigen detection. After fixation, cells were pelleted, washed twice with 1x wash buffer (Becton Dickenson, proprietary formulation), and resuspended in 100–200 μl of wash buffer.
[0109] FACS staining and analysis. FACS staining was performed by adding 2 μg of primary antibody (directly labeled or unlabeled) as shown in Table 4 for 20 minutes at 4°C. After incubating the cells with the antibody, the cells were washed twice with wash buffer. Optionally, for example, when the primary antibody was unlabeled, the cells were further immunolabeled with an appropriate secondary antibody bearing a detectable fluorophore, such as AlexaFluor 488. Appropriate isotype and secondary antibody controls were run alongside the primary staining reaction to allow for proper gating of channels during FACS analysis.
[0110] All cell populations were washed again with wash buffer and resuspended in 200 μl of PBS. Analysis of immunostained enriched heterogeneous renal cell populations was performed on a MACSQuant analyzer.
[0111] Results: Specific levels of expression of five nephrogenic markers were observed in a total of 18 enriched clinical samples of heterogeneous renal cell populations. See Tables 5 and 6.
[0112] [Table 5]
[0113] [Table 6]
[0114] Nephrin was also found to be expressed by between approximately 4.34 percent and 98.72 percent of cells in an enriched heterogeneous renal cell population with therapeutic potential.
[0115] Analysis of additional clinical samples of enriched heterogeneous renal cell populations was performed to again determine the expression levels of five nephrogenic markers. In addition to the five nephrogenic markers, specific levels of nephrin and podocin (which may be important for glomerular development during nephrogenesis) and RACK-1 were also determined. See Figure 1B.
[0116] Renal regeneration may require the utilization of mechanistic elements common to development and organogenesis. Expression of markers typically associated with the earliest signaling events in embryonic nephrogenesis indicates that enriched heterogeneous renal cell populations, prepared, for example, as described in Example 1, have dedifferentiated and acquired more renal progenitor-like characteristics. Thus, introduction of such enriched heterogeneous renal cell populations into diseased kidneys can trigger the initiation of key signaling cascades that normally mediate nephrogenesis but (in the context of adult parenchyma) can be interpreted as regeneration. Expression of nephrogenic markers SIX2, OSR1, LHX1, RET, and FGF8 can explain how enriched heterogeneous renal cell populations can confer therapeutic benefit, for example, through regenerative effects in diseased kidneys. For example, enriched heterogeneous renal cell populations prepared according to the method described in Example 1 demonstrated therapeutic effects, such as prolonged dialysis, reduced albumin-to-creatinine ratio, and increased eGFR, in patients requiring treatment for kidney disease. Next, we will briefly explain each nephrogenic marker and its role in nephrogenesis.
[0117] SIX2 is a member of a vertebrate gene family encoding a protein homologous to the Drosophila "sine oculis" homeobox protein. The SIX2 protein is a transcription factor that plays an important role in the development of several organs, including the kidney, skull, and stomach. During kidney development, SIX2 maintains multipotent nephron progenitor cells in the cap mesenchyme in an undifferentiated state by counteracting inductive signals emanating from the ureteric bud and cooperates with WNT9B to promote progenitor cell proliferation during regeneration. SIX2 can function independently of classical WNT signaling through its interaction with TCF7L2 and OSR1, thereby preventing the transcription of differentiation genes in the cap mesenchyme, such as WNT4. Furthermore, SIX2 acts independently of OSR1 and activates the expression of many cap mesenchymal genes, including GDNF and OSR1.
[0118] OSR1 is the earliest marker of intermediate mesoderm, which forms the gonads and kidneys. Its expression is not essential for the formation of intermediate mesoderm, but rather is essential for differentiation toward renal and gonadal structures. OSR1 acts upstream of and induces the expression of transcription factors LHX1, PAX2, and WT1, which are involved in early urogenital development. During normal kidney development, activation of the PAX2-EYA1-HOX11 complex and subsequent activation of SIX2 and GDNF expression enable ureteric bud branching and maintenance of cap mesenchyme, which forms nephrons. SIX2 maintains the self-renewal state of cap mesenchyme, and GDNF, via the GDNF-RET signaling pathway, is required for the attraction and branching of the developing ureteric bud. Within the developing kidney, OSR1-expressing cells give rise to mesangial cells, pericytes, ureteral smooth muscle, and the renal capsule. The cell type into which OSR1-expressing cells differentiate depends on the timing of expression loss: cells that will become part of the vasculature or ureteral epithelium lose OSR1 expression early (E8.5), while cells that will become nephrons lose expression late (E11.5). In mice lacking OSR1 expression, all three stages of nephrogenesis are affected, similar to mice with reduced expression of WT1 and PAX2, with abnormal Wolffian ducts, fewer mesonephric tubules, and defective metanephros and gonads that form the kidney. At embryonic day 10.5, embryos lacking OSR1 expression fail to develop a ureteric bud, which transitions to noncompacting metanephric mesenchyme. The lack of inductive signals from the ureteric bud, combined with reduced downstream PAX2 expression, results in kidney apoptosis and agenesis.
[0119] LHX1 is a transcription factor. In vertebrate embryos, the kidney originates from the intermediate mesoderm. The LIM class homeobox transcription factor LHX1 is expressed early in the intermediate mesoderm and is one of the first genes expressed in the renal mesenchyme. Depletion of LHX1 in Xenopus embryos results in the near-complete loss of the kidney field.
[0120] RET is necessary, among other things, for normal kidney development and sperm production (spermatogenesis). The RET protein spans the cell membrane, so one end of the protein remains inside the cell and the other end protrudes from the outer surface of the cell. This protein configuration allows the protein to interact with specific factors outside the cell and receive signals that help the cell respond to its environment. When molecules that stimulate growth and development (growth factors) attach to the RET protein, a complex cascade of chemical reactions is triggered inside the cell. These reactions direct the cell to undergo certain changes, such as dividing or maturing to acquire specialized functions.
[0121] The FGF8 gene encodes fibroblast growth factor 8 (FGF8). This protein is part of a family of proteins called fibroblast growth factors that are involved in many processes, including cell division, regulating cell growth and maturation, and prenatal development. FGF8 attaches (binds) to another protein on the cell surface called fibroblast growth factor receptor 1 (FGFR1), which triggers a cascade of chemical reactions within the cell.
[0122] A panel of nephrogenic markers expressed by enriched heterogeneous renal cell populations with therapeutic potential was identified. Expression of these markers provides evidence that cells of the enriched heterogeneous renal cell population have the ability to affect signaling cascades that mediate nephrogenesis or kidney regeneration, thereby providing a therapeutic effect. It is noted that there is some variability in marker expression, which is expected due to the autologous origin of the cells.
[0123] Example 3: Identification of transcript regulation that is mechanistically important for the therapeutic bioactivity of enriched heterogeneous kidney cell populations. Introduction: To further understand the mechanisms underlying the repair, restoration, and / or regenerative activities of enriched heterogeneous renal cell populations, genome-wide transcriptome profiling was performed on subpopulations of renal cells contained therein. The enriched heterogeneous renal cell population contains four component-enriched renal cell subpopulations (B2, B3, B4, and B5) prepared by density gradient separation of PreG (pre-gradient fractionation) material. In this example, the transcriptome profiles of rodent PreG material and the four component-enriched renal cell subpopulations (B2, B3, B4, and B5) that comprise the enriched heterogeneous rodent renal cell population were analyzed separately, compared, and contrasted. By analyzing each of the four component-enriched renal cell subpopulations (B2, B3, B4, and B5) separately and comparing their transcriptomic profiles with those of the PreG material, we were able to understand their respective contributions to the observed repair, restorative, and regenerative bioactivity of the enriched heterogeneous renal cell populations.
[0124] Materials and Methods / Preparation of Renal Cell Populations: Kidneys from three independent donors (5-week-old, male, isogenic Lewis laboratory rats) were used as starting material for three independent biological replicates of all renal cell populations and subpopulations characterized in this analysis. The preparation of selected bioactive primary renal cells from whole rat kidneys has been described in detail (AT, Guthrie, KI, Kelley, R. Methods Mol Biol 1001, 53, 2013; Kelley, R., et al. American Journal of Physiology & Renal Physiology 299, 1026, 2010; Kelley, R., et al. Cell Transplantation 22, 1023, 2013). Briefly, whole kidneys were harvested from 5-week-old male Lewis rats (Hilltop Labs, Scottsdale, PA, USA), and kidney tissue was enzymatically dissociated in a buffer containing 4.0 units / mL of dispase (Stem Cell Technologies, Inc., Vancouver, BC, Canada) and 300 units / mL of collagenase IV (Worthington Biochemical, Lakewood, NJ, USA). Red blood cells and debris were removed by centrifugation through 15% iodixanol (Optiprep™, Axis Shield, Norton, MA, USA). Primary renal cells were seeded onto tissue culture-treated polystyrene plates (NUNC, Rochester, NY, USA) and cultured in a 50:50 medium containing 5% fetal bovine serum (FBS), 2.5 μg EGF, 25 mg bovine pituitary extract (BPE), 1x ITS (insulin / transferrin / sodium selenite medium supplement), and antibiotic / antimycotic (all from Invitrogen, Carlsbad, CA, USA). Prior to cell isolation, primary renal cell cultures were transferred from atmospheric oxygen (21%) to a more physiologically relevant hypoxic environment (2%) for 24 hours to improve cell isolation efficiency.75 × 10 in 2 mL of unsupplemented KSFM (uKSFM). 6 Separation of primary kidney cell cultures prepared as individual cells was performed by centrifugation through a four-step iodixanol (OptiPrep, 60% wt / vol in uKSFM) density gradient (16%, 13%, 11%, and 7%) specifically layered for rodents in 15 mL conical polypropylene tubes, followed by centrifugation at 800 x g for 20 minutes (without interruption) at room temperature. After centrifugation, cellular subfractions were extracted from the gradient via pipette and collected as four distinct bands (B1–B4) and a pellet (B5). All bands were washed three times with sterile phosphate-buffered saline (PBS) before use. Pre-gradient samples ("PreG") and whole kidney tissue samples ("Macro") were collected from each rodent for comparison. The culture conditions used for each rodent cell population are summarized in Table 7 below.
[0125] [Table 7]
[0126] Materials and Methods / Transcript Analysis: RNA for genome-wide transcript analysis was prepared using a Qiagen RNA isolation kit according to the manufacturer's instructions. Genome-wide transcript analysis was performed on Affymetrix GeneChip Rat Genome 230 2.0 arrays (Wake Forest University Health Sciences Microarray Core Facility, Winston-Salem, NC) using 2 μg of RNA from each sample, normalized according to Table 8 below.
[0127] [Table 8]
[0128] Materials and Methods / Data Analysis: Affymetrix GeneChip data were normalized using RMA (Rafael et al., 2003. Nucleic Acids Research 31:e15). Gene expression profiles from each component-enriched renal cell subpopulation (B1, B2, B3, B4, B5) were compared with those in the PreG material using paired t-tests. Differentially expressed genes were detected by paired t-tests with P<0.05 and then analyzed using DAVID (http: / / david.abcc.ncifcrf.gov) to detect Gene Ontology (GO) categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that were significantly different between each fraction and the PreG. GO analysis used the GO biological process categories, GO-BP-FAT, provided by DAVID to minimize redundancy and increase specificity in GO terms. Bonferroni adjustments were applied to P values generated from GO and KEGG pathway analyses to correct for multiple testing. KEGG pathway plots were generated using Bioconductor's Pathview (Weijun Luo and Cory Brouwer. Bioinformatics, 29(14):1830-1831, 2013). QIAGEN's Ingenuity Pathway Analysis (IPA™, QIAGEN Redwood City, www.qiagen.com / ingenuity) was used to generate gene networks for GO categories.
[0129] Results / Subfraction B1: GO analysis of the B1 subpopulation for PreG material revealed cell cycle (P = 9.40 × 10 -4 ), cell division (P=9.81×10 -5), and cell cycle phase (P = 0.016) were significantly downregulated (Table 9). KEGG pathway analysis yielded similar results (Table 9). The downregulated cycle pathway genes were distributed across cell cycle phases, including cell growth (G1, G2), DNA replication (S), and mitosis (M). For example, key cell cycle regulatory proteins negatively regulated in B1 compared with PreG included CDK2, CDK7, CYCE, CDC45, ORC, CHK1, CHK2, MAD2, CDC20, and APC. Furthermore, GO / KEGG categories related to transcription regulation, including regulation of transcription (P = 0.001), regulation of RNA metabolic processes (P = 0.044), and spliceosome (P = 0.002), were significantly downregulated (Table 9).
[0130] [Table 9]
[0131] These transcriptomic data suggest that the B1 subpopulation represents a significantly lower proliferative and regenerative potential, consistent with the observed lack of functional impact of B1 cells on renal pathophysiology in rodent models of CKD (Bruce, AT, Guthrie, KI, Kelley, R. Methods Mol Biol 1001, 53, 2013; Kelley, R., et al. American Journal of Physiology & Renal Physiology 299, 1026, 2010; Kelley, R., et al. Cell Transplantation 22, 1023, 2013).
[0132] Significantly upregulated GO / KEGG categories in the B1 subpopulation for PreG material included cytokine-mediated signaling pathways involved in immune responses (P=0.023) and lysosomes involved in the digestion of foreign bodies and cellular waste products (P=4.44×10 -4) were included. Cell adhesion (P = 0.045) was also upregulated (Table 9). These data are again consistent with the observed lack of functional impact of B1 cells on renal pathophysiology in rodent models of CKD. The B1-enriched renal cell subpopulation is not a component of the enriched heterogeneous renal cell population.
[0133] Results / Subfraction B2: The transcriptome profile of B2 was found to be similar to PreG at the pathway level. No GO / KEGG categories were identified as significantly upregulated. Only one pathway, ECM-receptor interaction (rno04512), was found to be significantly downregulated (P=0.039) compared to PreG material. Consistent with the downregulation of ECM-receptor interaction, numerous ECM proteins, including collagen, laminin, reelin, tenascin, vitronectin, and thrombospondin (THBS), were significantly downregulated in B2. It is well known that excessive deposition of extracellular matrix (ECM) components causes tissue fibrosis (Liu Y. Kidney International 69, 213, 2006; Kisseleva and Brenner, 2008. Proc Am Thorac Soc 5: 338-42; El-Nahas, 2003. Kidney Int 64: 1553-63). Furthermore, renal fibrosis is a hallmark of the progression of chronic kidney disease (CKD) to end-stage renal disease.
[0134] In contrast to the negatively regulated transcriptome profile observed for ECM-associated genes, expression of the hyaluronan-mediated motility receptor (RHAMM; also known as CD168 or hyaluronan-mediated motility receptor (HMMR)) was specifically upregulated in the B2 subpopulation compared to PreG material (fold change = 1.114, P = 0.030). RHAMM expression has been directly linked to regenerative bioactivity in numerous in vitro and in vivo model systems. For example, RHAMM has been shown to promote angiogenesis, regeneration of 3D salivary gland spheroids, and tail and cell motility in Xenopus tadpoles. Therefore, increasing RHAMM expression levels may be beneficial for tissue regeneration (Pradhan-Bhatt et al., 2014. Laryngoscope 124: 456-461; Contreras et al., 2009. Development 136: 2987-96; Tolg et al., 2006. J Cell Biol 175: 1017-28; Savani RC, et al. 2001. J. Biol. Chem. 276 (39): 36770-8; Hall CL, et al. 1994.. J. Cell Biol. 126 (2): 575-88; Hamilton SR, et al. 2007. J. Biol. Chem. 282 (22): 16667-80). Furthermore, hyaluronic acid (HA), for which RHAMM is a receptor, is present throughout the interstitial space of the developing kidney (Bakala, H., et al., 1988. J Morphol 196: 1-14) and is an ECM component known to stimulate the differentiation of the ureteric bud into collecting ducts and the mesenchymal-epithelial transition of metanephric mesenchyme, independent of molecular weight. The significant upregulation of RHAMM in the B2 subpopulation and these data raise interesting possibilities for renal tissue engineering and cell-based medicine. As an example, scaffolds engineered to release HA of defined molecular weights at specific concentrations could be implanted into the kidney in the hopes of modulating regenerative outcomes.
[0135] Results / Subfraction B3: KEGG pathway analysis revealed that categories related to the complement and coagulation cascades were significantly upregulated in the B3 subpopulation compared with the PreG material (P = 0.008) (Table 10). Upregulated genes included complement component genes such as C2, C3, and C4, as well as coagulation-related genes such as fibrinogen (FG) and coagulation factor XIII (F13). The complement and coagulation systems are considered the "first line of defense" against injury and invaders (Choi G, et al. Swiss Med Wkly. 2006; 136:139-144). Therefore, upregulation of this pathway indicates an increased immune response. Consistent with the KEGG analysis, GO analysis also found a significant increase in humoral immune responses (P = 0.025) (Table 10). It is well established that multiple components of both the cellular and humoral immune systems contribute to repair, recovery, or regeneration outcomes in numerous organs and tissues, including the limbs, skeletal muscle, heart, and nervous system (Aurora and Olson, 2014. Cell Stem Cell 15: 14-25).
[0136] [Table 10]
[0137] Significantly downregulated GO categories in the B3 subpopulation were related to the regulation of actin polymerization and actin filament length (Table 10). Dynamic reorganization of the actin cytoskeleton is a major driver of cell migration. Inhibition of actin polymerization may have a negative impact on cell migration and therapeutic efficacy in the B3 subpopulation.
[0138] Results / Subfraction B4: The B4 subpopulation was observed to have functional consequences in rodent models of CKD. Consistent with its observed in vivo therapeutic bioactivity, it significantly enhanced vasculature development (P = 7.76 × 10 -7 ), vascular development (P = 1.36 × 10 -6 ), vascular morphogenesis (P=1.76×10 -6), angiogenesis (P=1.82×10 -6 ), and response to wounding ( P = 1.35 × 10 -5 Numerous regeneration-related GO categories, including angiogenesis, were found to be significantly upregulated in the B4 subpopulation compared to the PreG material (Table 11). The GO category angiogenesis is central to repair, restoration, or regeneration in the kidney, heart, and numerous other organs and tissues (Takiya and Borojevic, 2011. Kidney Int Suppl 1: 99-102; Kramann and Humphreys, 2014. Semin Nephrol 34: 374-83; Park and Gerecht, 2014. Development 141: 2760-9; Kaully et al., 2009. Tissue Eng Part B 15: 159-69). Key receptors central to angiogenesis and other regeneration-related signaling pathways, including CXCR4, TEK, FGFR1, and KDR, were found to be upregulated. Among these, the SDF1 / CXCR4 axis is central to renal repair, recovery, or regeneration in response to ectopic cell-based therapy (Togel and Westenfelder, 2011, Kidney Int Suppl 1: 87-89; Sharma et al., 2011, Stem Cells Dev 20: 933-46; Sagrinati, C., et al. Trends Mol Med 14, 277, 2008). In the GO category of response to wounds, many up-regulated genes, such as Notch1, Notch3, Timp3, Vwf, Adam15, Gas6, Igfbp1, and Tm4sf4, also belong to the GO categories of wound healing and tissue repair, tissue repair, or tissue regeneration. The significant up-regulation of these genes in response to PreG is also consistent with the regenerative bioactivity of subpopulation B4.
[0139] [Table 11]
[0140] Furthermore, cell adhesion-related GO categories were found to be significantly upregulated in B4 compared to PreG material (Table 11). Cell adhesion is essential for the incorporation and functional integration of transplanted cells into the host environment. Induction of cell adhesion genes may be beneficial for the homing of transplanted cells.
[0141] None of the analyzed pathways were found to be significantly downregulated in B4.
[0142] Results / Subfraction B5: Subpopulation B5 was found to be the most distinctive fraction compared to PreG material at the gene expression level. Forty GO / KEGG categories were significantly different from PreG (Tables 12 and 13).
[0143] [Table 12]
[0144] [Table 13]
[0145] The up-regulated GO / KEGG categories included cell adhesion, angiogenesis, ductal branching morphogenesis, cell morphogenesis, regulation of epithelial cell proliferation, blood vessel development, vascular morphogenesis, vasculature development, cellular component morphogenesis, cell morphogenesis, cell morphogenesis involved in differentiation, duct morphogenesis, organization and morphogenesis of cell processes, morphogenesis of cell parts, morphogenesis of branching structures, developmental maturation, and response to nutrients, etc. Most of these significantly up-regulated GO / KEGG categories are apparently involved in catalyzing repair, recovery, or regenerative outcomes.
[0146] As observed in B4, the key pro-angiogenic receptors CXCR4, TEK, and KDR were significantly upregulated in B5. Furthermore, the pro-angiogenic ligands PGF, ANGPT2, ANGPT4, VEGFA, and PDGFA were observed to be significantly upregulated in the B5 subpopulation compared to the PreG material. The regenerative bioactivity of these ligands is well established.
[0147] Some significantly differentially regulated pathways of particular interest included the canonical Wnt / β-catenin signaling pathway, which was significantly downregulated in the B5 subpopulation compared to the PreG material (Table 13). Wnt signaling is closely involved in nephrogenesis and organogenesis, but in the right circumstances can also have profibrotic effects and contribute to the maintenance of pathology (Kawakami et al., 2013. J Pathol 229: 221-31; Shkreli et al., 2011. Nat Med 18: 111-9; Cisternas et al., 2014. Curr Mol Med 14: 510-22). It is possible that the proper Wnt signaling bioactivity for B5 in the context of SRC may be its profibrotic effects, so any reduction in Wnt signaling would be a desirable outcome upon transplantation into fibrotic diseased kidneys (Cuevas et al., 2015. Biomed Res Int. Article ID 726012).
[0148] Interestingly, the GO category "tube branching morphogenesis" was also upregulated in the B5 subpopulation compared to the PreG material. This was intriguing, given that mammalian nephrogenesis is driven by an iterative process of branching morphogenesis between the ureteric bud, an outgrowth of the renal duct, and the surrounding metanephric mesenchyme. Continuing branching morphogenesis from the ureteric bud epithelium in response to signaling from the adjacent metanephric mesenchyme, in turn, leads to the induction of new aggregates of metanephric mesenchyme at the ureteric bud tip and the continuation of nephrogenic events. This iterative process continues along the radial axis of the developing kidney, directing the youngest nephrons toward the periphery (reviewed by Basu and Ludlow, 2012, Birth Defects Research Part C 96: 30-38). To this end, transplantation of enriched heterogeneous renal cell populations, such as SRCs, in adult rodent kidneys has been newly associated with the induction of nascent nephron-like structures (Basu, J., et al. Cell Transplantation 20, 1771, 2011).
[0149] Finally, interestingly, activation of the GO category "regulation of epithelial cell proliferation via the TGF-β1 signaling pathway" was noted as being consistent with a potential role for enriched heterogeneous renal cell populations, such as SRCs, in promoting the proliferation of host tubular epithelial cells. Indeed, for this reason, the transplanted enriched heterogeneous renal cell populations, such as the 5 / 6N x We observed that treatment with enriched heterogeneous renal cell populations, such as SRC, promoted proliferation of renal tubular cells in the model. + The number of proliferating cells specifically increased, and this compartment-specific proliferation may be a direct indicator of treatment outcome: epithelial proliferation leads to replenishing kidney function, whereas interstitial proliferation leads to fibrosis.
[0150] A significant downregulation of numerous GO / KEGG categories related to protein metabolism in the B5 subpopulation compared to the PreG material was observed, which may simply indicate a reduced overall metabolic rate for the B5 subpopulation compared to the PreG material.
[0151] Abstract: Enriched heterogeneous renal cell populations, such as SRCs, are produced by iodixinol gradient centrifugation of PreG material. Iodixinol gradient centrifugation of PreG material results in the separation of PreG material into five subpopulations, B1-B5. Transcriptomic profiling of the B1-B5 subpopulations identified key transcriptomic networks and associated signaling pathways and mechanisms of action that may underlie enriched heterogeneous renal cell populations, such as SRCs, as evidenced by their repair, restorative, and regenerative bioactivity in the treatment of chronic kidney disease. Significant differences in the subpopulations B2–B5 included in the final enriched heterogeneous renal cell population product compared to PreG material included downregulation of GO / KEGG categories related to ECM-receptor interactions in subpopulation B2, upregulation of GO / KEGG categories related to immune response and regulation of actin polymerization in subpopulation B3, upregulation of GO / KEGG categories related to repair, recovery, regeneration, and cell adhesion in B4, and 40 differentially regulated GO / KEGG categories, including many categories clearly related to repair, recovery, or regenerative activity in B5. Subpopulation B1, not included in the enriched heterogeneous renal cell population, showed significant downregulation of GO / KEGG categories related to cell cycle and transcriptional regulation and significant upregulation of GO / KEGG categories related to inflammation compared to PreG material.
[0152] Taken together, the transcriptomic data suggest that therapeutically used enriched heterogeneous renal cell populations, such as SRCs, catalyze repair, restoration, or regeneration outcomes in the kidney, in part, by activating multiple transcriptomic networks associated with promoting regeneration while simultaneously suppressing alternative transcriptional pathways that may promote the continued progression of renal disease and pathophysiology.
[0153] Example 4: Identification of developmental pathways mechanistically important for the regenerative bioactivity of enriched heterogeneous human kidney cell populations used to treat chronic kidney disease. Introduction: Further building on the rodent data in Example 3, transcriptomic and epigenomic analyses were performed on enriched heterogeneous human kidney cell populations prepared for use in clinical trials. Renal Autologous Cell Therapy (REACT) is a novel regenerative medicine candidate for the treatment of chronic kidney disease, diabetic nephropathy, and congenital anomalies of the kidney and urinary tract (Stavas 2021. "Protocol and Baseline Data on Renal Autologous Cell Therapy Injection in Adults with Chronic Kidney Disease Secondary to Congenital Anomalies of the Kidney and Urinary Tract." Blood Purif 50(4-5):678-683, Stenvinkel P, Wadstroem J, Bertram T, Detwiler R, Gerber D, Brismar TB, et al., "Implantation of autologous selected renal cells in diabetic chronic kidney disease stage 3 and stage 4 - a clinical trial of a 'first in human' trial" Kidney Disease Stages 3 and 4—Clinical Experience of a "First in Human" Study. Kidney Int Rep. 2016 1(3):105-13). REACT is formulated using an enriched heterogeneous kidney cell population (referred to in this example as SRC or SRC population) prepared or manufactured from an initial cell population derived from a subject's own kidney biopsy (referred to in this example as BRC or BRC population). Comparison of the transcriptomic and epigenomic profiles of the human SRC population versus the BRC population was conducted to confirm and further explore the mechanisms underlying the repair and restorative activities of human SRC used to treat kidney disease.
[0154] Materials and Methods / Preparation of SRCs for Treatment of Chronic Kidney Disease: Methods for preparing selected renal cells from renal tissue biopsies have been previously described in detail (Bruce, AT, Guthrie, KI, Kelley, R., "Ex vivo culture and separation of functional renal cells." Methods Mol. Biol. 1001, 53, 2013; Halberstadt et al., 2013, Methods Mol. Biol.).
[0155] Materials and Methods / cDNA Library Construction: For library construction, RNA was extracted from each cell population (n = 6). After DNase I treatment and quality control (QC), library construction was performed using 200 ng of high-quality total RNA. mRNA was isolated using magnetic beads containing oligo(dT). After random fragmentation of mRNA by adding fragmentation buffer, dNTPs, RNase H, and DNA polymerase I were added, followed by cDNA synthesis using mRNA templates and random hexamer primers. Short fragments were purified and dissolved in EB buffer, followed by end repair and single nucleotide A (adenine) addition. The short fragments were then ligated with sequencing adapters. Double-stranded cDNA libraries were completed through size selection and PCR enrichment. During the QC process, sample libraries were quantified and qualified using an Agilent 2100 Bioanalyzer and an ABI StepOnePlus Real-Time PCR System. Finally, the qualified RNA-seq libraries were sequenced using an Illumina NovaSeq6000 at CD Genomics (Shirley, NY) after pooling according to effective concentration and expected data volume.
[0156] Materials and Methods / Bioinformatics Analysis: Basic statistics on the quality of raw reads were performed using the FastQC tool (http: / / www.bioinformatics.babraham.ac.uk / projects / fastq). Sequencing adapters and low-quality data were removed using Trimmomatic (version 0.36) (Juhling, F., et al., "Metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data." Genome Res, 2016. 26(2): pp. 256-62). The filtered clean reads were mapped to the reference genome using HISAT2 (Kanehisa, M., et al., "KEGG for linking genomes to life and the environment." Nucleic Acids Res, 2008. 36 (Database issue): p. D480-4) to obtain location and gene features. The Cuffquant and Cuffnorm components of Cufflinks software were used to quantify transcript and gene expression levels using the location information of the reads mapped to genes. The gene expression levels of each single gene, as well as the number of genes at different expression levels, were analyzed. DESeq was used to analyze DEGs for samples with biological replicates, and EBSeq was used for samples without replicates. During the analysis, samples were first grouped so that later comparisons could be made between every two groups as control-treatment pairs. During this process, a fold change of ≥2 and an FDR of <0.01 were set as screening criteria.Gene Ontology (GO - Gene Ontology Consortium, 2000) enrichment analysis is an internationally standardized set of classification systems for describing gene function that attempts to identify GO terms significantly associated with genes encoding differentially expressed proteins. GO terms are divided into three major categories: 1) cellular components: used to describe subcellular structures, location, and recognition of macromolecular complexes such as nucleoli, telomeres, and initial complexes; 2) molecular functions: used to describe genes, gene products, individual functions such as carbohydrate binding or ATP hydrolase activity; and 3) biological processes: used to describe products encoded by genes involved in biological processes such as mitosis or purine metabolism. KEGG pathways were used to identify pathways in which specific genes were significantly enriched compared to the overall genomic background. The formula for this analysis is:
number
[0157] Materials and Methods / Reduced Representation Bisulfite Sequencing (RRBS): Genomic DNA was isolated from cell samples (BRC0, SRC, n = 4) using the Nucleon™ BACC Genomic DNA Extraction Kit (GE Healthcare, Life Sciences), and double-stranded DNA content was quantified using the Qubit High Sensitivity Assay (Life Technologies). One microgram of genomic DNA from each cell sample was digested with MspI (NEB), followed by end preparation and adapter ligation using the Premium RRBS Kit (Diagenode). Size selection was performed using AMPure XP beads (Beckman Coulter, Inc.) to obtain a DNA fraction of the MspI digestion product enriched for the most CpG-rich regions within the 150-350 bp range. Bisulfite treatment was then performed using ZYMO's EZ DNA Methylation-Gold Kit. The converted DNA was then amplified by 12 cycles of PCR using 25 μl of KAPA HiFi HotStart Uracil+ReadyMix (2x) and 8-bp index primers at a final concentration of 1 μM each, followed by cleanup using AMPure XP beads. The constructed RRBS library was sent to CD Genomics (Shirley, NY) for sequencing and bioinformatics analysis. Briefly, the library was quantified using the Quant-iT dsDNA HS Assay Kit (Invitrogen) on a Qubit fluorometer and sequenced on an Illumina Hiseq platform using a paired-end 150-bp strategy.
[0158] Materials and Methods / RRBS Data Analysis: Basic statistics on the quality of raw reads were performed using the FastQC tool (www.bioinformatics.babraham.ac.uk / projects / fastq). Sequencing adapters and low-quality data were then removed using Trimmomatic (version 0.36) (Juhling, F., et al., "Metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data." Genome Res, 2016. 26(2): pp. 256-62). The bisulfite sequences were mapped to the reference genome using BSMAP software with the parameters "-n 0 -g 0 -v 0.08 -m 50 -x 1000" (Kanehisa, M., et al., "KEGG for linking genomes to life and the environment." Nucleic Acids Res, 2008. 36 (Database issue): p. D480-4). Alignment statistics were collected, where only uniquely mapped reads were retained for subsequent analysis. Only methylated cytosines with a sequence depth coverage of at least 5 were used. Methylation occurred when the base in the alignment was C, and conversely, no methylation occurred when the base in the alignment was T. The methylation level of an individual cytosine was calculated as the ratio of the sequencing depth of the confirmed methylated CpG cytosine to the total sequencing depth of the individual CpG cytosine, i.e., ML = mC / (mC + umC), where ML is the methylation level, and mC and umC represent the number of reads corresponding to methylated C and unmethylated C, respectively.We used the software metilene (version 0.2-7) to identify differentially methylated regions (DMRs) using a binary segmentation algorithm combined with two-dimensional statistical tests (parameters: -M 300 -m 5 -d 0.1 -t 1 -f 1 -v 0.7) (Bruce et al., 2013. "Ex vivo culture and separation of functional renal cells." Methods Mol Biol 1001:53-640). Gene Ontology (GO, http: / / www.geneontology.org / ) enrichment analysis of DMR-associated genes was applied to identify biological processes of interest. Pathways with a Q value of 0.05 or less were considered significantly enriched in DMR-associated genes. Based on the DMR annotation results and the KEGG database (Sha et al., 2021. "Genome-wide transcriptional profiling of selected renal cells (SRC): identification of functional pathways for regenerative bioactivity in treatment of chronic kidney disease." submitted paper), we performed functional enrichment analysis on genes whose gene body and upstream and downstream regions (2k upstream, gene body, and 2k downstream) were observed to overlap with DMRs.
[0159] Results / Differentially expressed transcripts that distinguish between cells in the SRC and BRC0 populations A total of n=6 individual donors were used to prepare total RNA and cDNA for library construction and RNA-seq analysis as described in Materials and Methods. A total of 221 DEGs discriminating between the SRC and BRC0 populations were identified. These 221 DEGs consist of 119 genes that were specifically upregulated in SRC compared to BRC0 and 102 genes that were specifically downregulated in SRC compared to BRC0. The top 20 genes that were upregulated and downregulated in SRC compared to BRC0 are listed in Tables 14 and 15, respectively. The false discovery rate (FDR) for these transcripts was 10. -6 , which reflects very high statistical significance.
[0160] [Table 14]
[0161] [Table 15]
[0162] Examination of the genes listed in Tables 14 and 15 revealed that the top up-regulated DEGs that clearly distinguished SRC from BRC0 included genes mediating aspects of cell cycle control (CDKN2A, IL11, TGFβ2), extracellular matrix reorganization (FN1, CRISPLD2, COL1A1, LOX), and signaling pathways involved in development (RUNX2, LFNG, BDNF). The top down-regulated DEGs that clearly distinguished SRC from BRC0 included genes involved in tight junction assembly and organization (CLDN3), glucose metabolism (UPP1, KLF15), protein glycosylation (GYLTL1B, MAN1C1, GALNT9), and water and ion transport (AQP1, SLC47A1, WNK2, CASR), as well as signaling pathways involved in development (RAI2, PLVAP, SHISA3, PARM1, CASR). Other notable upregulated DEGs (not shown in Table 14 but still highly significant) included BDNF, FGF11, FOXE1, WNT5A, WNT10A, TGFβ1, and IGFBP3, all of which are involved in aspects of cell-cell signaling related to development and morphogenesis.
[0163] Among these genes, expression of CDKN2A is likely simply a manifestation of long-term passaging of cell populations in vitro, as this gene is an established marker of cellular senescence (Famulski & Halloran, 2005; "Molecular events in kidney aging", Curr Opin Nephrol Hyperten 14:243-248).
[0164] Regarding IL11, although it is intimately involved in many aspects of fibrotic and inflammatory diseases in the kidney and other organs (Cook and Schafer, 2020; “Hiding in Plain Sight: Interleukin-11 Emerges as a Master Regulator of Fibrosis, Tissue Integrity, and Stromal Inflammation”, Ann Rev Med. 71: 263), IL11 has a potential role in particularly relevant regenerative bioactivities. IL11 has been shown to be required for organ regeneration in Xenopus laevis through the induction and maintenance of undifferentiated progenitor populations across multiple cell lineages during tail regeneration (Tsujioka et al., 2017; "Interleukin-11 induces and maintains progenitors of different cell lineages during Xenopus tadpole tail regeneration." Nature Commun. 8: 495).
[0165] Not only the TGF-β2 gene but also other members of the TGF-β superfamily are known to be important mediators of kidney development and regulate nephron number either directly or indirectly (Sims-Lucas et al., 2008, "Augmented and accelerated nephrogenesis in TGF-β2 heterozygous mutant mice," Pedr. Res 63: 607-612). Furthermore, TGF-β2 has been shown to act synergistically with FGF2 to induce the formation of numerous renal tubules in isolated rodent metanephric mesenchymal explants (Plisov et al., 2001, "TGF-β2, LIF, and FGF2 cooperate to induce nephrogenesis," Development 128: 1045).
[0166] The branching morphogen CRISPLD2 (also known as LDL1) has been shown to have a specific localization pattern to the developing ureteral branching tip (UBT) (Rutledge et al., 2017. "Cellular heterogeneity in the ureteric progenitor niche and distinct profiles of branching morphogenesis in organ development", Development 144:3177). The observation of CRISPLD2 / LDL1 expression suggests that CRISPLD2 secreted from metanephric mesenchymal cells promotes branching morphogenesis of the kidney collecting system, which is comparable to its putative effect on the early stages of lung bud branching (Quinlan et al., 2007. "LGL1, a novel branching morphogen in developing kidney, is induced by retinoic acid." Am J Physiol Renal Physiol; 293(4):F987-93).
[0167] The LOX and LOX-like protein family is known to play multiple roles in development and organogenesis through its biological activity in the assembly and reorganization of the extracellular matrix. LOX and LOX-like proteins are involved in the development of numerous tissues and organs, including the brain, spinal cord, lung, heart, aorta, teeth, bone, cartilage, muscle and tendon, skin, and uterus (Wei et al., 2020; "Role of the lysyl oxidase family in organ development (Review)," Exp. Ther. Med. 20: 163-172).
[0168] LFNG is one of three Notch ligands, and its expression is involved in the establishment of proximal / distal polarity and demarcation in the renal corpuscle. The Notch pathway establishes proximal polarity, which is achieved through the comma body and S-body stages, and is essential for the development of proximal tubules and podocytes (O-Brian and McMahon, 2014. "Induction and patterning of the metanephric nephron." Semin Cell Dev Biol. 36:31-38). Expression of LFNG and the closely related glycosyltransferase radical fringe has been observed in the anterior dorsal region of the proximal pronephros at the tailbud stage of development in Xenopus laevis. LFNG expression has been found to be absent from the distal and proximal portions of the developing nephron in E14.5 mouse embryos, but is strongly detected in the future proximal tubule (similar to the expression of the Notch ligand DLL1). By E17.5, LFNG expression was found to be restricted to a portion of the developing nephron in the kidney periphery, suggesting that LFNG may be regulated by NOTCH signaling in cells of the future proximal tubule (Leimeister et al., 2003. "Expression of Notch pathway genes in the embryonic mouse metanephros suggests a role in proximal tubule development." Gene Expression Patterns 3: 595-598).
[0169] Analysis of BDNF expression in the human fetal kidney revealed that BDNF is localized to the apical regions of epithelial cells within developing primitive glomerular structures and mesenchymal-derived tubules. BDNF is detected in the distal tubules as differentiation progresses, but its expression is not observed in uninduced mesenchyme, suggesting that BDNF is not involved in early inductive events but rather in later stages of nephron organization (Huber et al., 1996. "Neurotrophins and neurotrophin receptors in human fetal kidney." Developmental biology 179: 369-381). Interestingly, BDNF has also been shown to mediate podocyte repair in vitro and in vivo through a microRNA-dependent increase in cytoskeletal actin polymerization (Li et al., 2015. "BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization." J Pathol 235: 731-744). Morpholino-mediated knockdown of BDNF in zebrafish larvae resulted in abnormal glomerular morphology, reduced podocyte numbers, and misexpression of the podocyte markers nephrin and podocin (Endlich et al., 2018. "BDNF: mRNA expression in urine cells of patients with chronic kidney disease and its role in kidney function." J Cell Mol Med. 22: 5265-5277).
[0170] WNT5A is known to be essential for kidney development, and congenital anomalies of the kidney and urinary tract (CAKUT) in patients with Robinow syndrome are associated with mutations in the WNT5A gene. Abnormalities in ureteric tree development, tubular epithelial cell organization, and basement membrane integrity have been observed in WNT5A-deficient rodents (Pietila et al., 2016. "Wnt5a Deficiency Leads to Anomalies in Ureteric Tree Development, Tubular Epithelial Cell Organization and Basement Membrane Integrity Pointing to a Role in Kidney Collecting Duct Patterning." Plos One 11: e0147171), as well as in ectopic ureteric bud (UB)-induced duplication of the ureter and kidney. During early UB formation, WNT5A mutant embryos exhibit dysregulated metanephric mesenchyme (MM) positioning, resulting in abnormal spatiotemporal interactions between the MM and Wolffian ducts and inappropriate GDNF signaling with the Wolffian ducts. Furthermore, cell proliferation in mutant MMs is significantly reduced compared to controls, suggesting a critical role for WNT5A / ROR2 signaling in MM morphogenesis to ensure correct epithelial tubule formation in the developing ureteric bud (Nishita et al., 2014. "Role of Wnt5a-Ror2 Signaling in Morphogenesis of the Metanephric Mesenchyme during Ureteric Budding"; Mol Cell Biol 16: 3096-3105).WNT5A signaling may also be involved in podocyte development and glomerular podocyte recovery from injury by reorganizing the actin cytoskeleton via the planar cell polarity pathway (Babayeva et al., 2011. "Planar cell polarity pathway regulates actin rearrangement, cell shape, motility, and nephrin distribution in podocytes." AJPRP F549-60).
[0171] IGFBP3 has been documented in mature and differentiated cells of the collecting system and ureter in the human fetal kidney, where it likely acts to regulate the bioactivity of IGFs during nephrogenesis (Matsell et al., 1994. "Expression of insulin-like growth factor and binding protein genes during nephrogenesis." Kidney Int 46: 1031-42).
[0172] Results / GO analysis of the DEG gene set shows enrichment of classifiers related to development: A Protein Analysis Through Evolutionary Relationships (PANTHER) overrepresentation analysis was performed to identify GO categories that were specifically enriched in the DEG gene set compared to the entire human genome. The results of the PANTHER analysis were generally consistent with those shown in Tables 14 and 15, where the DEG dataset shows enrichment of GO identifiers related to development, including cell communication, cell differentiation, cell-cell adhesion, developmental processes, nervous system development, and system development. Key pathways highlighted in the REACTOME pathway analysis of the entire DEG set included developmental biology, cell cycle, cell-cell communication, extracellular matrix organization, nervous system, signal transduction, and gene expression (transcription) pathways.
[0173] We also performed an analysis of the GO-BPs (biological processes), GO-CCs (cellular components), and GO-MFs (molecular functions) of all DEGs in SRC vs. BRC0 compared to the whole human genome. Specific enrichment of DEGs compared to the whole human genome was observed for the following development-related GO-BP categories: cellular process, single-organism process, biological regulation, metabolic process, response to stimulus, multicellular organism process, developmental process, signal transduction, localization, organization or biosynthesis of cellular components, multiorganism process, immune system process, reproduction, reproductive process, movement, biological adhesion, behavior, presynaptic process involved in chemical synaptic transmission, cell killing, and cell aggregation. Consistent with previous reports indicating that exosome-mediated intercellular communication is an important mechanism of action for SRC (Bruce et al., 2013. "Ex vivo culture and separation of functional renal cells." Methods Mol Biol 1001:53-64), we noted enrichment of the following GO-CC categories in the SRC / BRC0 DEG set: extracellular domain, extracellular domain part, supramolecular complex, synapse, other organism, and other organism part. Finally, we observed enrichment of DEGs compared to the whole human genome for the following GO-MF categories: structural molecule activity, molecular function regulator, transporter activity, nucleic acid-binding transcription factor activity, and molecular transducer activity. Additional details regarding the gene composition and ancestry / descendance of each of these GO classifiers can be found at amigo.geneontology.org.
[0174] Results: KEGG analysis of the DEG gene set demonstrates enrichment of development-related classifiers. KEGG annotation of the major identified metabolic and signaling pathways associated with the SRC / BRC0 DEG gene set was also performed. The KEGG cellular process classifiers specifically enriched in the DEG gene set were broadly related to the formation, organization, and maintenance of epithelial cell junctions, cell cycle control, and regulation of stem cell pluripotency: adherens junctions, p53 signaling pathway, tight junctions, signaling pathways regulating stem cell pluripotency, regulation of actin cytoskeleton, endocytosis, cell cycle, and focal adhesions. Furthermore, numerous key signaling pathways related to development, cell cycle control, and regeneration were also enriched in major KEGG categories: AMPK, mTOR, WNT, HIF-1, JAK-STAT, RAP-1, TNF, TGFβ, MAPK, FOXO, HIPPO, and PI3K-AKT signaling pathways, as well as cytokine-cytokine receptor interactions and ECM-receptor interactions.
[0175] The scatter plot shown in Figure 2 is a graphical representation of the KEGG enrichment analysis results. In this figure, the degree of KEGG enrichment was measured by the richness coefficient, q-value, and the number of enriched genes in a specific pathway. The richness coefficient refers to the ratio of the number of differentially expressed genes located in a pathway to the total number of annotated genes located in the pathway. The larger the richness coefficient, the higher the degree of enrichment. The q-value is the corrected p-value after multiple hypothesis testing. The q-value ranges from [0, 1], with the closer to zero, the more significant the enrichment. The major KEGG pathways related to kidney regeneration included the TGF-β signaling pathway, the HIPPO signaling pathway, the FOXO signaling pathway, the cell cycle, ECM-receptor interaction, and pyrimidine metabolism.
[0176] Focusing specifically on the up-regulated DEG set, the following KEGG classifiers were found to be significant: adherens junctions, endocytosis, cell cycle, regulation of actin cytoskeleton, p53 signaling pathway, signaling pathway regulating stem cell pluripotency, and focal adhesions. Additional pathways significant in the up-regulated DEG set included Rap1 signaling pathway, HIF1 signaling pathway, JAK-STAT signaling pathway, TGF-β signaling pathway, MAPK signaling pathway, TNF signaling pathway, and HIPPO signaling pathway (Figure 3). A topGO analysis of the up-regulated DEG gene set is shown in Figure 3. Key GO-BP identifiers specifically related to regeneration included intrauterine embryonic development, epidermal growth factor receptor signaling pathway, G protein-coupled receptor signaling pathway, Notch signaling pathway, and negative regulation of epithelial cell proliferation.
[0177] Specific investigation of the downregulated DEG set showed enrichment for the following KEGG classifiers: focal adhesion, apoptosis, lysosome, cell cycle, tight junction, and endocytosis, as well as for the signaling pathways: HIPPO, Hedgehog, and AMPK. TopGO analysis of the downregulated DEG set showed enrichment for the following BP classifiers: EGFR signaling pathway, Notch signaling pathway, GPCR signaling pathway, gastrointestinal morphogenesis, cardiac looping, and negative regulation of epithelial cell proliferation.
[0178] Results / Epigenomic profiling of SRC and BRC0 populations: A comparison of differentially methylated regions (DMRs) between SRC and BRC0 is presented as a violin boxplot in Figure 4, demonstrating that the SRC genome is proportionally more hypermethylated and less hypomethylated than the BRC0 genome (n = 4). Based on the DMR annotation results, functional enrichment analysis was performed on genes whose gene bodies and upstream and downstream regions (2k upstream, gene body, and 2k downstream) overlapped with DMRs. GO-BP classifiers for the most highly enriched DMR-associated genes in SRC versus BRC0 included cell adhesion, signal transduction, and negative / positive regulation of RNA polymerase transcription. KEGG pathways identified as highly enriched in the SRC population compared with BRC0 included regulation of the actin cytoskeleton, proteoglycans in cancer, focal adhesions, endocytosis, cAMP signaling pathway, RAS signaling pathway, RAP1 signaling pathway, PI3-AKT signaling pathway, MAPK signaling pathway, and HIPPO signaling. Broadly, these classifiers were diagnostic of genes involved in extracellular matrix organization and reorganization, as well as signaling pathways related to organismal development and cell proliferation. These classifiers were also consistent with classifiers previously identified in analyses of DEG sets.
[0179] Similarly, based on the distribution of DMRs across the genome, functional enrichment analysis of gene promoter regions (1.5 km upstream from the transcription start site and 0.5 km downstream from the transcription start site) revealed overlapping genes. According to this analysis, GO classifiers associated with DMR-associated genes included regulation of the actin cytoskeleton, endocytosis, cAMP signaling pathway, cell adhesion molecule CAM, and RAP1 signaling pathway. Also noteworthy for the largest fold change in SRC vs. BRC0 was leukocyte transendothelial migration, a key inflammatory step related to wound healing and tissue regeneration. Furthermore, KEGG classifiers associated with DMR-associated genes included regulation of the actin cytoskeleton, cAMP signaling pathway, signaling pathway regulating stem cell pluripotency, RAS signaling pathway, RAP1 signaling pathway, PI3K-AKT signaling pathway, endocytosis, cell adhesion molecule CAM, and leukocyte transendothelial pathway. These classifiers were largely consistent with those previously identified in the DEG set.
[0180] Results / Summary: Overall, SRCs of human origin exhibited enriched DEG sets in development-related GO and KEGG classifiers. KEGG cellular process classifiers specifically enriched in DEG gene sets were broadly related to the formation, organization, and maintenance of epithelial cell junctions, cell cycle control, and regulation of stem cell pluripotency. Similar enrichment patterns were observed in DMR gene sets. Based on these and other expression data presented herein, SRCs may mediate in vivo regeneration of the kidney and improve clinical outcomes in patients with kidney disease, in part by activating mechanistic pathways that are equivalent to aspects of embryonic nephrogenesis that ultimately lead to the formation of de novo kidney-like tissue at injured or diseased sites.
[0181] Example 5: Enriched heterogeneous renal cell populations administered to subjects with moderate to advanced type 2 diabetes-associated CKD - Evaluation of expression levels of nephrogenic markers and potential relationship with clinical outcome Introduction: With the understanding that enriched heterogeneous renal cell populations, such as the SRCs referred to in this example, may mediate regenerative effects on diseased kidneys by affecting signaling cascades that mediate de novo nephrogenesis, SRCs administered to clinical trial subjects with moderate to advanced type 2 diabetes-associated CKD were assessed for expression levels of nephrogenic markers and compared accordingly with the patient's clinical response.
[0182] Materials and Methods / Preparation of SRCs for Administration: All patients in the clinical trial underwent standard percutaneous renal biopsies to isolate kidney cells from which their SRCs were prepared for administration. SRCs were prepared from kidney biopsies as described in Examples 1 and 4.
[0183] Materials and Methods / SRC Phenotypic Marker Analysis: SRCs in suspension were centrifuged at 300 × g for 5 minutes at room temperature. The resulting SRC pellet was washed once with Dulbecco's phosphate-buffered saline (DPBS) before being fixed in BD Fixation / Permeabilization Solution (BD Biosciences, catalog number 554714) for 20 minutes at 4°C. Fixed cells were centrifuged at 500 × g for 5 minutes at room temperature. The cell pellet was resuspended in BD Permeabilization / Wash buffer. The resuspended cells were divided into aliquots (20 μL containing 150,000 cells) and then incubated with 1 μg of primary antibody for 1 hour at 4°C. At the end of this incubation, cells were pelleted, washed with BD Permeabilization / Wash buffer, pelleted again, and resuspended in 150 μL of DPBS. For antibodies not directly conjugated to a fluorophore, 1 μg of secondary antibody was incubated with the cells for an additional 30 minutes before being washed and resuspended in DPBS. The cells were then analyzed by flow cytometry.
[0184] Materials and Methods / FACS Analysis of SRC: To determine whether SRC contain markers for cap mesenchyme, nephrogenic stroma, and ureteric bud, cells were screened for membrane proteins that identify these specific components. Screening was performed using the following immunoreagents: goat anti-rabbit IgG H&L (Alexafluor 488) (Abcam Inc., catalog no. ab150077), rabbit polyclonal against NPHS2 (Abcam Inc., catalog no. ab50339), rabbit monoclonal against nephrin (Y17R) (Abcam Inc., catalog no. ab136894), Alexafluor 488 rabbit monoclonal against RET (EPR2871) (Abcam Inc., catalog no. ab237105), polyclonal rabbit IgG isotype control (Abcam Inc. ab37415), Six2 antibody (H-4) PE (Santa Cruz, catalog no. sc-377193 PE), OSR1 antibody (Santa Cruz, catalog no. sc376545 PE), Lhx1 monoclonal IgG2a (Santa Cruz, catalog no. sc515631 PE), RET rabbit monoclonal antibody (Abcam Inc. catalog number ab237105), goat polyclonal secondary antibody against RB IGG (H&L)-Alexa Fluor 488 (Abcam Inc. catalog number ab150077), Alexa Fluor™ 647 mouse IgG2a,κ isotype control (BD, catalog number 557715), full-length Fgf8 monoclonal (Abcam, catalog number ab89550), rabbit IgG isotype control [PE] (Novus Biologicals, catalog number NBP2-36463PE), and PE mouse IgG1,κ isotype control (BD, catalog number 555749).
[0185] Materials and Methods / FACS Phenotypic Marker Analysis: Phenotypic marker analysis was performed by pelleting at least 50,000 SRCs in a 1.5 mL microcentrifuge tube and fixing the cells in 100 μL of BD Fixation / Permeabilization Solution for 20 minutes at 4°C. The microcentrifuge tube was then placed in a microcentrifuge at 500 × g for 3 minutes to pellet the fixed cells, which were then washed once with 500 μL of BD Permeabilization / Wash Buffer. The washed pellet was resuspended in 20 μL of BD Permeabilization / Wash Buffer and incubated with 1 μg of primary antibody for 1 hour at 4°C. The cells were washed once with 500 μL of BD Permeabilization / Wash Buffer, resuspended in 20 μL of BD Permeabilization / Wash Buffer, and incubated with 1 μg of secondary antibody for 30 minutes at 4°C. A final wash was performed with 500 μL of BD Permeabilization / Wash Buffer. The pellet was resuspended in 150 μL of DPBS, and the cells were analyzed by flow cytometry.
[0186] Results / Marker Expression Analysis of SRC: The results of marker expression analysis of SRC administered to subjects in clinical trials are shown in Table 16.
[0187] [Table 16]
[0188] For example, consistent with previous analyses shown in Example 2, SRCs from clinical trial subjects expressed markers from the nephrogenic marker panel, as well as other markers, including nephrin, podocin, and RACK-1. SRCs from clinical trial subjects also contained similar percentages of cells expressing the previously described markers. Correlations of various markers provided evidence of their co-expression (see Figures 5A-5H).
[0189] Further analysis of SRC marker expression revealed that subjects identified as intermediate / high responders (improved eGFR) showed higher expression of various biomarkers, with a trend toward significance for Six2 and significance for LHx1, compared to subjects identified as low responders (improved eGFR slope but no improvement in eGFR) (Table 16). These analyses provide further evidence that SRC may mediate de novo nephrogenesis by demonstrating that cells in the SRC population have higher expression levels of nephrogenic markers, thereby enhancing their ability to mediate regenerative and restorative activities, which may provide a therapeutic benefit to diseased kidneys.
Claims
1. 1. A method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, comprising: (i) determining whether cells of the enriched heterogeneous renal cell population express at least one nephrogenic marker; (ii) identifying the enriched heterogeneous renal cell population as having therapeutic potential if cells of the enriched heterogeneous renal cell population are determined to express the at least one nephrogenic marker; wherein the at least one nephrogenic marker comprises one or more of SIX2, OSR1, LHX1, RET, and FGF8.
2. The method of claim 1, wherein (i) determining comprises determining the percentage of cells in the enriched heterogeneous renal cell population that express at least one nephrogenic marker.
3. The method of claim 1 , wherein the at least one nephrogenic marker comprises SIX2.
4. The at least one nephrogenic marker comprises SIX2, 3. The method of claim 2, wherein the enriched heterogeneous renal cell population is identified as having therapeutic potential when greater than 0% and up to about 6.0% of the cells of the enriched heterogeneous renal cell population are determined to express SIX2.
5. The at least one nephrogenic marker comprises OSR1, 3. The method of claim 2, wherein the enriched heterogeneous renal cell population is identified as having therapeutic potential if greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population are determined to express OSR1.
6. The at least one nephrogenic marker comprises LHX1, 3. The method of claim 2, wherein the enriched heterogeneous renal cell population is identified as having therapeutic potential when about 8% to about 58% of the cells of the enriched heterogeneous renal cell population are determined to express LHX1.
7. The at least one nephrogenic marker comprises RET, The method of claim 2, wherein the enriched heterogeneous renal cell population is identified as having therapeutic potential when greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population are determined to express RET.
8. The at least one nephrogenic marker comprises FGF8, 3. The method of claim 2, wherein the enriched heterogeneous renal cell population is identified as having therapeutic potential when greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population are determined to express FGF8.
9. The at least one nephrogenic marker is (a) SIX2 and OSR1, or (b) SIX2 and LHX1, or (c) SIX2 and RET, or (d) SIX2 and FGF8, or (e) OSR1 and LHX1, or (f) OSR1 and RET, or (g) OSR1 and FGF8, or (h) LHX1 and RET, or (i) LHX1 and FGF8, or (j) RET and FGF8, or (k) SIX2, OSR1, and LHX1, or (l) SIX2, OSR1, and RET, or (m) SIX2, OSR1, and FGF8, or (n) SIX2, LHX1, and RET, or (o) SIX2, LHX1, and FGF8, or (p) SIX2, RET, and FGF8, or (q) OSR1, LHX1, and RET, or (r) OSR1, LHX1, and FGF8, or (s) OSR1, RET, and FGF8, or (t) LHX1, RET, and FGF8, or (u) SIX2, OSR1, LHX1, and RET, or (v) SIX2, OSR1, LHX1, and FGF8, or (w) SIX2, LHX1, RET, and FGF8, or (x) SIX2, OSR1, RET, and FGF8, or (y) OSR1, LHX1, RET, and FGF8, or (z) SIX2, OSR1, LHX1, RET, and FGF8 The method of claim 1 , comprising:
10. The at least one nephrogenic marker is (a) SIX2 and OSR1, where: Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2 and greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1; or (b) SIX2 and LHX1, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2 and greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1; or (c) SIX2 and RET, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2 and greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET; or (d) SIX2 and FGF8, wherein Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2 and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (e) OSR1 and LHX1, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1 and greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1; or (f) OSR1 and RET, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1 and greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET; or (g) OSR1 and FGF8, wherein: Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1 and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (h) LHX1 and RET, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1 and greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET; or (i) LHX1 and FGF8, Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1 and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (j) RET and FGF8, wherein Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (k) SIX2, OSR1, and LHX1, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, and greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1; or (l) SIX2, OSR1, and RET, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, and greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET; or (m) SIX2, OSR1, and FGF8, or identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (n) SIX2, LHX1, and RET, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, and greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET; or (o) SIX2, LHX1, and FGF8, or identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6.0% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (p) SIX2, RET, and FGF8, Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (q) OSR1, LHX1, and RET, wherein Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, and greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET; or (r) OSR1, LHX1, and FGF8, or identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (s) OSR1, RET, and FGF8, or identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (t) LHX1, RET, and FGF8, Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (u) SIX2, OSR1, LHX1, and RET, where Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, and greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET; or (v) SIX2, OSR1, LHX1, and FGF8, Identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (w) SIX2, LHX1, RET, and FGF8, identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (x) SIX2, OSR1, RET, and FGF8, or identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (y) OSR1, LHX1, RET, and FGF8, or identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8; or (z) SIX2, OSR1, LHX1, RET, and FGF8, 3. The method of claim 2, comprising: identifying the enriched heterogeneous renal cell population as having therapeutic potential if it is determined that greater than 0% and at most about 6% of the cells of the enriched heterogeneous renal cell population express SIX2, greater than 0% and at most about 70% of the cells of the enriched heterogeneous renal cell population express OSR1, greater than about 8% of the cells of the enriched heterogeneous renal cell population express LHX1, greater than 0% and at most about 85% of the cells of the enriched heterogeneous renal cell population express RET, and greater than 0% and at most about 59% of the cells of the enriched heterogeneous renal cell population express FGF8.
11. determining whether cells of the enriched heterogeneous renal cell population express RACK-1; identifying the enriched heterogeneous renal cell population as having therapeutic potential if the cells of the enriched heterogeneous renal cell population are further determined to express RACK-1; The method of any one of claims 1 to 10, further comprising:
12. 12. The method of claim 11, wherein the enriched heterogeneous renal cell population is identified as having therapeutic potential when it is determined that at least about 85% of the cells of the heterogeneous renal cell population express RACK-1.
13. 1. A method for identifying an enriched heterogeneous renal cell population as having therapeutic potential, comprising: determining the expression level of one or more of the genes RHAMM, C2, C3, C4, fibrinogen, coagulation factor XIII, TEK, KDR, Notch1, Notch3, Timp3, Vwf, Adam15, Gas6, Igfbp1, and Tm4sf4 by cells of the enriched heterogeneous renal cell population; identifying the enriched heterogeneous renal cell population as having therapeutic potential if the level of expression of the one or more genes by cells of the enriched heterogeneous renal cell population is increased compared to the level of expression of the one or more genes by cells of a control renal cell population; A method comprising:
14. A pharmaceutical composition comprising an enriched heterogeneous renal cell population identified according to the method of any one of claims 1 to 13.
15. 15. The pharmaceutical composition of claim 14, further comprising hyaluronic acid.
16. 15. The pharmaceutical composition of claim 14 for treating kidney disease in a patient in need of such treatment.
17. 15. Use of the pharmaceutical composition of claim 14 in the manufacture of a medicament for treating kidney disease.
